

# British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma

Matthew R Banks<sup>1</sup>, David Graham<sup>1</sup>, Marnix Jansen<sup>2</sup>, Takuji Gotoda<sup>3</sup>, Sergio Coda<sup>4</sup>, Massimiliano di Pietro<sup>5</sup>, Noriya Uedo<sup>6</sup>, Pradeep Bhandari<sup>7</sup>, , Mark Pritchard<sup>8</sup>, Ernst J. Kuipers<sup>9</sup>, Manuel Rodriguez-Justo<sup>2</sup>, Marco Novelli<sup>2</sup>, Krish Ragunath<sup>10</sup>, Neil A Shepherd<sup>11</sup>, Mario Dinis-Ribeiro<sup>12</sup>

1. Division Gastroenterology, University College London Hospitals, London, UK
2. Dept Pathology, University College London Hospitals, London, UK
3. Division of Gastroenterology and Hepatology (Nihon University Hospital), Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
4. London Photonics Group, Imperial College London,
5. MRC Cancer Unit, University of Cambridge, UK
6. Osaka International Cancer Institute, Osaka, Japan
7. Q A Hospital, Cosham, Portsmouth, UK
8. Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, UK
9. Erasmus MC University Medical Center Rotterdam, Netherlands
10. Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK
11. Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, UK
12. Dep. Gastroenterology , Instituto Português de Oncologia do Porto, Portugal

Corresponding Author and GDG chair:

Dr Matthew R Banks

Division of Gastroenterology, University College London Hospitals NHS Trust

250 Euston Road, London, NW1 2PG

Matthew.banks2@nhs.net

Word count: 31,000 including references and tables

## Abbreviations

GA	Gastric atrophy
GIM	Gastric intestinal metaplasia
CAG	Chronic atrophic gastritis
ESD	Endoscopic submucosal dissection
EMR	Endoscopic mucosal resection
GDG	Guideline development group
LGD	Low grade dysplasia
HGD	High grade dysplasia
MRB	Matthew R Banks
AGREE	Appraisal of Guidelines for Research and Evaluation
COI	Conflict of interest
OR	Odds ratio
HR	Hazard ratio

RR	Relative risk
SIR	Standardised incidence ratio
PGI	Pepsinogen I
PGII	Pepsinogen II
WLE	White light endoscopy
FGP	Fundic glandular polyp

## **Keywords**

Gastric adenocarcinoma, gastric atrophy, gastric intestinal metaplasia, gastric dysplasia, endoscopic mucosal resection, endoscopic submucosal dissection.

## **Acknowledgements**

We acknowledge the BSG for support in the development of these guidelines. We thank Dr Marc Tischkowitz for his contribution to the genetics of gastric cancer, Reader and Honorary Consultant in Medical Genetics, Academic Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Box 238, Level 6 Addenbrooke's Treatment Centre, Cambridge Biomedical Campus, Cambridge CB2 0QQ.

## **1. Abstract**

Gastric adenocarcinoma carries a poor prognosis in part due to the late stage of diagnosis. Risk factors include *H. pylori* infection, family history of gastric cancer, in particular hereditary diffuse gastric cancer and pernicious anaemia. The stages in the progression to cancer include chronic gastritis, gastric atrophy (GA), intestinal metaplasia (GIM) and dysplasia. The key to early detection of cancer and improved survival is to non-invasively identify those at risk prior to endoscopy. However, although biomarkers may help in the detection of patients with chronic atrophic gastritis (CAG), there is insufficient evidence to support their use for population screening. High quality endoscopy with full mucosal visualisation is an important part of improving early detection. Image enhanced endoscopy combined with biopsy sampling for histopathology is the best approach to detect and accurately risk stratify GA and GIM. Biopsies following the Sydney protocol from the antrum, incisura, lesser and greater curvature allow both diagnostic confirmation and risk stratification for progression to cancer. Ideally biopsies should be directed to areas of GA or GIM visualised by high quality endoscopy. There is insufficient evidence to support screening in a low risk population (undergoing routine diagnostic OGD) such as the UK, but endoscopic surveillance every three years should be offered to patients with extensive GA or GIM. Endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) of visible gastric dysplasia and early cancer has been shown to be efficacious with a high success rate and low rate of recurrence, providing specific quality criteria are met.

## **2. Executive Summary**

Gastric adenocarcinoma continues to be a frequent cause of death in the world and is the 16<sup>th</sup> most common cancer in the UK. The most common stages in the progression to gastric adenocarcinoma are GA and GIM which are collectively known as CAG. These conditions are principally caused by *H. pylori* infection and less commonly by autoimmune gastritis. The key

to having a significant impact on the prognosis of gastric adenocarcinoma and its economic burden is to accurately identify individuals at greatest risk and intervene prior to them establishing cancer through recognised efficacious therapies, including endoscopic resection. The BSG endoscopy committee agreed to create a guideline to provide statements and recommendations on the prevalence, risks, diagnosis, treatment, surveillance, and screening of gastric pre- and early gastric malignant lesions. The principal patient group are those found to have GA, GIM, gastric epithelial dysplasia or early gastric adenocarcinoma limited to the mucosal or superficial submucosal layers. The target users include gastroenterologists, gastrointestinal surgeons, pathologists, endoscopists and general practitioners. We followed The Appraisal of Guidelines for Research and Evaluation (AGREE II) Instrument and the quality of the evidence was assessed following The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) System.

A series of statements, recommendations and suggestions are proposed to ensure that there is consistency of practice such that patients with gastric pre- and early gastric malignant lesions are provided with optimal care. These recommendations are listed below:

1. **We recommend *H. pylori* eradication to reduce the risk of gastric adenocarcinoma development in patients who have gastric atrophy** (Evidence level: High quality; Grade of recommendation: high; Level of agreement: 100%)
2. **We suggest that *H. pylori* eradication may be of some benefit to reduce the risk of developing gastric adenocarcinoma in those who already have *H. pylori*-associated gastric intestinal metaplasia, dysplasia or cancer.** (Evidence level: High quality; Grade of recommendation: weak; Level of agreement: 100%)
3. **We do not recommend the use of biomarkers as a screening tool in areas with a low incidence of gastric adenocarcinoma, such as the UK.** (Evidence level: Low quality; Grade of recommendation: weak; Level of agreement: 93%)
4. **We recommend patients at higher risk for gastric adenocarcinoma, including gastric atrophy and gastric intestinal metaplasia should undergo a full systematic endoscopy protocol of the stomach with clear photo documentation of gastric regions and pathology. We suggest a minimum examination time of 7 minutes.** (Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 100 %)
5. **Gastric atrophy and intestinal metaplasia may be detectable by white light endoscopy alone, however the accuracy is poor. Therefore, we do not recommend establishing a diagnosis or risk-stratification using white light endoscopy alone.** (Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 93%)
6. **We recommend image-enhanced endoscopy is the best imaging modality to accurately detect and risk-stratify gastric atrophy and gastric intestinal metaplasia** (Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 100%)

7. **We recommend that endoscopic appearances on white light endoscopy suggestive of gastric atrophy or gastric intestinal metaplasia require escalation to high resolution, image-enhanced endoscopy and, where available, magnification endoscopy** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)
8. **We recommend that the location and extent of gastric atrophy and gastric intestinal metaplasia should be clearly documented with photo-evidence. Endoscopic grading should be documented as distal gastric (affecting antrum or incisura - low risk) or proximal gastric (affecting the corpus with or without the antrum and incisura - high risk).** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 93%)
9. **We recommend that patients with image-enhanced features of chronic atrophic gastritis should undergo biopsies for confirmation of endoscopic diagnosis; biopsies are directed at mucosal sites within Sydney protocol areas where enhanced imaging reveals gastric intestinal metaplasia. Biopsies should be collected in separate containers and labelled as either 'directed' or 'random' to corroborate endoscopic staging assessment** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 93%)
10. **We recommend that endoscopic appearances on white light endoscopy of gastric dysplasia and early gastric cancer (differences in colour, loss of vascularity, slight elevation or depression, nodularity, thickening, and abnormal convergence or flattening of folds) require escalation to image-enhanced endoscopy and, where available, magnification endoscopy** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)
11. **We recommend image-enhanced endoscopy is the best imaging modality to accurately diagnose and stage gastric dysplasia and early gastric cancer** (Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 100%)
12. **We suggest that a baseline endoscopy with biopsies should be considered in individuals 50 years and over, with laboratory evidence of pernicious anaemia, defined by vitamin B12 deficiency and either positive gastric parietal cell or intrinsic factor antibodies. As gastric atrophy affects the corpus in pernicious anaemia, biopsies should be taken from the greater and lesser curves** (Evidence level: low quality; Grade of recommendation: weak; Level of agreement: 93%)
13. **We recommend endoscopic surveillance every 3 years should be offered to patients diagnosed with extensive gastric atrophy or gastric intestinal metaplasia defined as that affecting the antrum and body** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)
14. **We do not recommend surveillance in patients with gastric atrophy or gastric intestinal metaplasia limited just to the gastric antrum unless there are additional risk factors such as a strong family history of gastric cancer or persistent *H. pylori* infection, then we suggest 3 yearly surveillance.** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 93%)

15. **We recommend patients with non-visible low-grade dysplasia should undergo a second endoscopy with enhanced imaging and extensive biopsy sampling, followed by a repeat endoscopy within 1 year if no visible neoplasia is detected. If there is persistent, non-visible low-grade dysplasia, endoscopy should be repeated annually thereafter.** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)
16. **We recommend patients with non-visible high-grade dysplasia should undergo a second endoscopy with enhanced imaging and extensive biopsy sampling. We recommend on-going surveillance at 6-monthly intervals for persistent, non-visible high-grade dysplasia. High grade dysplasia should be discussed at the regional upper GI cancer MDT and referred to a clinician with the appropriate expertise.** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)
17. **We recommend that all gastric dysplasia and early gastric adenocarcinoma should be resected in an en-bloc fashion (EMR technique can achieve en-bloc excision for lesions  $\leq 10$ mm in size but only ESD technique can ensure en-bloc excision for lesions  $> 10$ mm in size)** (Evidence level: high quality; Grade of recommendation: strong; Level of agreement: 100%)
18. **We recommend that complete (R0) endoscopic resection of gastric dysplasia and early gastric adenocarcinoma with the following features should be considered as curative:**
  - 1) **Low-grade dysplasia**
  - 2) **High-grade dysplasia**
  - 3) **Well or moderately differentiated intramucosal adenocarcinoma, irrespective of size and without ulceration**
  - 4) **Well or moderately differentiated intramucosal adenocarcinoma,  $< 3.0$  cm in size if ulcerated**
  - 5) **Well or moderately differentiated submucosal adenocarcinoma,  $< 3.0$  cm in size, with superficial submucosal invasion (Sm1;  $< 500$  micron submucosal invasion as measured in a straight line from the deepest fibre of the muscularis mucosae)**
  - 6) **Poorly differentiated intramucosal adenocarcinoma,  $\leq 2.0$  cm in size** (Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 93%)
19. **The histopathological features of early gastric adenocarcinoma associated with a higher risk of lymph node metastasis after endoscopic resection include:**
  - 1) **Poorly differentiated submucosal cancer, irrespective of invasion depth below muscularis mucosae**
  - 2) **Signet ring cancer**
  - 3) **Lympho-vascular invasion**
  - 4) **Depth of submucosal invasion  $\geq 500$  microns as measured in a straight line from the deepest fibre of the muscularis mucosae** (Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 93%)
20. **We do not recommend the use of NSAIDs or cyclooxygenase-2 (COX-2) inhibitors to reduce the risk of progression of pre-malignant lesions of the**

**stomach.** (Evidence level: Moderate; Grade of recommendation: Strong; Level of agreement 100%)

21. **We do not recommend the use of antioxidants as a means to reduce the prevalence of pre-malignant gastric lesions.** (Evidence level: Moderate; Grade of recommendation: Strong; Level of agreement 100%)
22. **We suggest endoscopic screening should be considered in individuals aged 50 or older with multiple risk factors for gastric adenocarcinoma (males, smokers, pernicious anaemia), in particular those with a first degree relative with gastric cancer.** (Evidence level: low quality; Grade of recommendation: weak; Level of agreement: 100%)
23. **We do not recommend endoscopic screening for gastric adenocarcinoma in the UK population** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)
24. **We recommend that the number of gastric polyps (or estimated number), location of polyps, and size of the largest polyp should be clearly documented** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)
25. **We recommend that gastric polyps other than fundic gland polyps should be biopsied for histopathological assessment** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)
26. **We recommend that photo-documentation should be undertaken for all polyps or representative polyps if numerous** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)
27. **We recommend that if adenomas or hyperplastic polyps are present, the background mucosa should be endoscopically assessed for gastric atrophy, gastric intestinal metaplasia, *H. pylori*, and synchronous neoplasia** (Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 100%)
28. **We recommend that all adenomas should be resected when clinically appropriate and safe to do so** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)
29. **We recommend that a follow up gastroscopy should be performed at 12 months after complete endoscopic excision of adenomas, then on-going surveillance gastroscopy annually when appropriate** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 93%)
30. **We suggest that hyperplastic polyps >1cm, pedunculated morphology, and those causing symptoms (obstruction, bleeding) should be resected. If present, *H. pylori* should be eradicated prior to re-evaluation for endoscopic therapy** (Evidence level: low quality; Grade of recommendation: weak; Level of agreement: 100%)

31. **We suggest enhanced endoscopic imaging is used to aid characterisation of gastric polyps when there is diagnostic uncertainty following white light examination** (Evidence level: low quality; Grade of recommendation: weak; Level of agreement: 93%)

Three pathways have been created to allow a quick reference to the management of CAG, gastric dysplasia and gastric epithelial polyps (Figure 1).

### 3. **Background**

Gastric adenocarcinoma is a major cause of cancer mortality worldwide (1–3). In the UK in 2016, there were 5,314 cases of gastric cancer which has been declining gradually with the incidence of *H.pylori* infection. Although there has been a decline in the incidence over the last 50 years, recent studies have demonstrated an increasing incidence of gastric adenocarcinoma among young white people in the US, alongside a Swedish study demonstrating an increasing incidence of pre-malignant gastric lesions among adults aged 35-44 years (4,5). These studies may suggest that historically declining gastric adenocarcinoma incidence rates may alter. At present within the UK, gastric cancer is the 16<sup>th</sup> most common cancer, within Europe it is the 6<sup>th</sup> most common cancer, and worldwide it is the 5<sup>th</sup> most common (1–3). Importantly, with the exception of Japan and South Korea, the majority of gastric cancers worldwide are diagnosed at a late stage resulting in poor prognosis with a 29% average 5-year survival (3,6). The UK all stage average 5-year survival rate is 18%, compared to an 80% average 5-year survival for stage 1A (3). Clearly, Japan's earlier stage of diagnosis and superior 5-year survival highlights the need for earlier recognition and treatment to overcome this bleak prognosis (7).

The key to having a significant impact on the prognosis of gastric cancer and its global economic burden is to accurately identify the individuals who are at greatest risk and intervene prior to gastric cancer development through recognised efficacious therapies, including endoscopic resection. The canonical model for cancer progression in the stomach is the Correa sequence which outlines a stepwise linear progression from chronic gastritis through GA, GIM, dysplasia, and finally invasive cancer (8). This model was amended to involve the role of *H. pylori* as the prime causative environmental agent (9) and has remained the dominant model since. Diagnosis and surveillance of higher risk patients in this cascade has been proposed as a strategy to reduce the mortality and morbidity of gastric adenocarcinoma.

The first international guidelines on the Management of Precancerous conditions and Lesions in Stomach (MAPS) were published in 2012 by an international guidelines development group (10). These have not yet been revised. There is significant heterogeneity of practice in regards to the management of pre- and early malignant gastric lesions in the UK, partly because few endoscopists follow the MAPS guidance.

### 4. **Objectives**

The objectives of these guidelines are to summarise the current evidence base and to provide recommendations on the diagnosis, risks, and management of gastric pre- and early malignant lesions including GA, GIM, dysplasia and early adenocarcinoma. These guidelines are intended for the UK population.

## 5. Methodology

The guideline was commissioned by the BSG in May 2015 and the proposal approved by Clinical Standards and Services Committee. The guideline was developed in line with the BSG Guideline Process (11). The purpose of the guideline was to provide guidance to healthcare professionals who are involved in the care of patients at risk of gastric cancer, including gastroenterologists, gastrointestinal surgeons, pathologists, endoscopists and general practitioners. The Appraisal of Guidelines for Research and Evaluation (AGREE II) Instrument (May 2009) (12) was used to guide the methodology. The chair (MRB) convened a guideline development group (GDG), consisting of clinicians and patients with experience of, or in the management of these conditions. Members of the GDG were selected to ensure the relevant professional bodies and specialities were represented including gastroenterologists, surgeons and pathologists. GDG members were required to declare any conflict of interests (COI). The scope and purpose of the guidelines were initially discussed by the GDG on 20<sup>th</sup> July 2015 at the first consensus meeting, following which a set of key questions were created. The key questions were sub-divided into clinical groups including diagnosis, treatment, surveillance, screening, and research (Table 1). The GDG then voted anonymously on the relevance of each question to the guidelines and those with less than 75% agreement were excluded. The GDG then met in London on 17<sup>th</sup> September 2015 for a second consensus meeting to discuss the agreed key questions, agree on methodology, and allocate leads and sub-groups to each question. Each lead and subgroup formulated a set of clinical questions pertinent to each key question using the PICO (Patients, Interventions, Controls and Outcomes) system, within which these four critical components were pre-defined as precisely as possible. The importance of each PICO outcome was ranked numerically by the sub-groups on a 1 to 9 scale (7 to 9 – critical; 4 to 6 – important; 1 to 3 – of limited importance) according to the clinical importance of each. Those 3 or less were excluded.

**Table 1**  
**Key questions, sub-groups and leads**

Question	Lead	Sub-group
<b>Diagnosis: overview</b>		
What are the epithelial glandular pre-cancerous lesions of the stomach, what is their prevalence within the UK and what risk do they incur ?	Dr David Graham	Matthew Banks, Ernst Kuipers, Mario Dinis-Ribeiro, Marnix Jansen, Marco Novelli, Manuel Rodriguez-Justo, Neil Shepherd
Are there groups of individuals (Without known pre-cancerous lesions) known to be at increased risk of glandular gastric cancer e.g. Family history, ethnic origin, genotype and phenotype ?	Dr Massimiliano di Pietro	Matthew Banks, Sergio Coda, David Graham, Noriya Uedo
Who should be screened for helicobacter pylori to reduce gastric cancer and how should they be screened? Does eradication prevent progression to glandular gastric cancer ?	Prof Mark Pritchard	Matthew Banks, Takuji Gotoda, Ernst Kuipers, David Graham



What blood tests are useful in the management of pre-cancerous gastric lesions? Can they be applied for population screening, monitoring those at risk or those with known lesions ?	Dr David Graham	Matthew Banks, Mario Dinis-Ribeiro, Mark Pritchard
<b>Diagnosis: Endoscopy</b>		
Outside the recommendations within the UK guidelines for the quality of endoscopy are there further processes that are suggested for the detection and diagnosis of pre or early malignant lesions of the stomach ?	Prof Takuji Gotoda	Matthew Banks, Krish Rangunath, David Graham, Sergio Coda
How does one identify pre or early malignant lesions and ensure accurate documentation when reporting? Is a station based approach beneficial and are there mucosal features that identify these lesions (including recognizing the atrophic border)?	Mr Sergio Coda	Matthew Banks, Takuji Gotoda, Noriya Uedo, Pradeep Bhandari, Krish Rangunath, David Graham
What biopsy strategy should be adopted for the sampling and reporting of the pre- or early malignant stomach? Should all those undergoing routine endoscopy be biopsied or are there groups to target ?	Dr Marnix Jansen	Matthew Banks, David Graham, Sergio Coda, Marco Novelli, Manuel Rodriguez-Justo, Neil Shepherd
What histopathological and imaging modalities are suggested for the staging of glandular pre- and early gastric malignant lesions of the stomach ?	Mr Sergio Coda	Marnix Jansen, Matthew Banks, David Graham, Sergio Coda, Marco Novelli, Manuel Rodriguez-Justo, Neil Shepherd
<b>Surveillance</b>		
Should individuals with pre- malignant gastric glandular lesions undergo surveillance? If so, what are the recommendations?	Dr Matthew Banks	Mario Dinis-Ribeiro, David graham, Massimiliano di Pietro, Ernst Kuipers
<b>Treatment: Endoscopy</b>		
What lesions are amenable for endoscopic removal? How should these lesions be removed? Are there criteria on histopathological assessment that determine prognosis and follow up?	Prof Pradeep Bhandari	Matthew Banks, Krish Rangunath, Takuji Gotoda, Noriya Uedo, David Graham.
<b>Treatment: Pharmacological</b>		
Is there a role for other pharmacological therapies e.g. COX inhibitors and anti-oxidants ?	Dr David Graham	Matthew Banks
<b>Screening</b>		
Is there evidence to support the introduction of a population screening programme for glandular gastric cancer?	Dr Matthew Banks	Mark Pritchard, David Graham

<b>Gastric polyps</b> What are the epithelial gastric polyps and how should they be managed ?	Dr Matthew Banks	Sergio Coda, Mark Pritchard, Pradeep Bhandari
<b>Research</b>		
Are there recommendations for future research into the diagnosis and management of pre- and early malignant lesions of the stomach ?	Dr Matthew Banks	Marnix Jansen, David Graham

## Literature searches, evidence synthesis and grading of evidence

A literature search was undertaken by each sub-group with pre-defined search terms, electronic databases utilised (Pubmed, Embase, Cochrane and Medline), and the time period covered. Where appropriate, conference abstracts were used to help formulate recommendations, provided that these were of sufficient scientific rigour.

The PICO's were used to guide the search for evidence and the highest quality studies were prioritised. Systematic reviews or meta-analyses were selected initially. Where systematic reviews, meta-analyses, or critically-appraised articles were unavailable, lower levels of evidence were selected. Where reviews utilise poor quality studies such as that by Spence et al (13), for example where the review was based upon small, often single centre cohort studies resulting in high levels of heterogeneity, this is discussed in the evidence review and highlighted in the evidence tables. In this instance, more weight is given to larger studies utilising large databases, which are likely to be more accurate. This hierarchy of searching was performed in a pyramidal sequence from top (High quality) to bottom (Low quality) cascading from recently published systematic reviews of RCTs or observational studies; to RCTs; and subsequently to observational studies providing no evidence is available from the higher quality categories. The selected evidence was tabulated in evidence table categorising each study into the study design, intervention/clinical question, participants/Population, reference standard, results and conclusions/Comments.

Although randomised controlled studies are deemed the most appropriate type of study to assess the effectiveness of an intervention, other types of studies were included to assess types of effectiveness, such as ways of delivering service or outcomes from registries in clinical practice. If evidence from studies was weak or contradictory, searches for alternative sources were undertaken to see if the evidence concurred or contradicted (triangulation of searches). All available negative studies were included in the searches. The subgroups discussed the external validity of the studies and whether the study outcomes are applicable to the target population for the guidelines. Literature searches were transparent and reproducible to reduce 'dissemination biases'.

All evidence tables and references were downloaded to a shared reference manager (*F1000 Workspace*), to which all GDG members had access. Shortly before the statements were finalised, a further literature search was undertaken. The quality of the evidence was assessed following The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) terminology using table 2 (14). Evidence is graded as high, moderate, low, and very low quality (Table 2).

The body of evidence for many questions was of low quality. Thus many statements were based on the consensus of the GDG given the limitations of the evidence.

**Table 2: Evidence level**

Evidence level	
High quality	One or more well-designed and well-executed randomized controlled trials (RCTs) that yield consistent and directly applicable results This level also means that further research is very unlikely to change our confidence in the estimate of effect
Moderate quality	RCTs with important limitations (i.e., biased assessment of the treatment effect, large loss to follow-up, lack of blinding, unexplained heterogeneity), indirect evidence originating from similar (But not identical) populations of interest, and RCTs with very small numbers of participants or observed events. In addition, evidence from well-designed controlled trials without randomization, from well designed cohort or case-controlled analytic studies, and from multiple time series with or without intervention is in this category. This level also means that further research will probably have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality	Observational studies would typically be rated as low quality because of the risk for bias. <sup>1</sup> This level also means that further research is very likely to have an important impact on our confidence in the estimate of effect and will probably change the estimate
Very low quality <sup>2</sup>	Evidence is conflicting, of poor quality, or lacking, and hence the balance of benefits and harms cannot be determined. Any estimate of effect is very uncertain as evidence is either unavailable or does not permit a conclusion

<sup>1</sup>Quality of evidence based on observational studies may be rated as moderate or even high, depending on circumstances under which evidence is obtained from observational studies. Factors that may contribute to upgrading the quality of evidence include a large magnitude of the observed effect, a dose-response association, or the presence of an unobserved effect when all plausible confounders would decrease the observed effect

<sup>2</sup>Insufficient evidence to determine for or against routinely providing a service

## Recommendations

Recommendations were made by each subgroup pertaining to the PICOs and graded as above with the strength of each recommendation. Recommendation strength is based upon 4 factors:

1. Balance between desirable and undesirable effects (not considering cost)
2. Quality of the evidence across critical/important outcomes
3. Patients' values and preferences
4. Costs (resource utilisation)

There are 2 grades of recommendations: *Strong* where the benefits clearly outweigh risks and burden ('*We recommend*'); *Weak* where the benefits closely balanced with risks/burden ('*We suggest*').

Once consensus was reached within the sub-group, the level of agreement for the recommendations was obtained from the whole GDG by anonymised voting. Level of agreement was sub-divided into 5 categories: Strongly agree, agree, undecided, disagree, and strongly disagree. All comments were used to amend recommendations where appropriate and a second round of voting was undertaken for any modifications. All results and comments were anonymously sent to the GDG Chairman (MRB). Where the GDG level of agreement was

consistently below 90% for strongly agree and agree after three rounds of voting, the recommendation was excluded.

## **6. Summary of Statements, Recommendations & Suggestions**

### **6.1 Pathogenesis, diagnosis and epidemiology of pre and early malignant gastric lesions**

#### **6.1.1 Pathogenesis and epidemiology of pre and early malignant gastric lesions**

*What are the pre-cancerous lesions of the stomach, what is their prevalence within the UK, and what risk do they confer?*

**Patients with gastric atrophy & gastric intestinal metaplasia have an increased risk of gastric adenocarcinoma. Increased severity of atrophy & extent of intestinal metaplasia is associated with an increased risk of cancer.** (Evidence level: moderate quality; Level of agreement: 100%)

**Visible low-grade gastric dysplasia has an increased risk of prevalent high-grade dysplasia and gastric adenocarcinoma** (Evidence level: low quality; Level of agreement: 100%)

**Non-visible low-grade gastric dysplasia increases the risk of gastric adenocarcinoma, but the magnitude of this risk is unknown** (Evidence level: low quality; Level of agreement: 93%)

**Gastric high-grade dysplasia carries a significant risk of progression to gastric adenocarcinoma** (Evidence level: moderate quality; Level of agreement: 100%)

#### **Gastric atrophy (GA), gastric intestinal metaplasia (GIM) and dysplasia**

For the purposes of this guideline chronic atrophic gastritis (CAG) collectively includes GA and GIM. It is important to define the histopathology of the pre-malignant stomach in order to understand progression to cancer and its endoscopic appearances. The normal gastric mucosa is divided into two compartments, and includes the gastrin and mucus secreting glands of the antrum and the acid and pepsinogen secreting oxyntic glands of the corpus. GA is defined as the loss of pre-existent glands native to the gastric compartment. The two phenotypic features of GA include the loss of glandular mass with fibrosis of the lamina propria and replacement of the native gastric glands by metaplastic or pseudopyloric glands.

The Correa cascade describes the stepwise progression of precursor lesions towards intestinal-type gastric cancer (9). *H. pylori* infection initiates the cascade through non-atrophic chronic gastritis, GA, GIM, and, finally, dysplasia (15).

Chronic atrophic gastritis encompasses both GA and GIM

### **Gastric atrophy (GA)**

GA is diagnosed histopathologically by two specific features: The presence of chronic inflammatory cells, including lymphocytes and plasma cells that expand the lamina propria, and the loss of the pre-existent gastric glands.

There is inconsistency in the histopathological diagnosis and severity of GA between pathologists resulting in low interobserver agreement by histopathologists when staging GA using the OLGA (Operative Link for Gastritis Assessment) Staging System, based upon biopsies taken using the Sydney protocol (16,17). Recent studies however, have demonstrated that accurate endoscopic staging of the severity of GA are strongly linked to gastric adenocarcinoma risk and that the interobserver and intraobserver agreement of endoscopic severity assessment, in experienced hands, is moderate to excellent (16,18).

The prevalence of CAG (including GA) worldwide correlates with the prevalence of *H.pylori*-associated gastritis, increases with age and tends to be slightly more common in men. Prevalence is typically determined utilising gastroscopy and serum pepsinogen. In Western populations, the prevalence varies from 0-8.3 % depending upon age (4,19–21). Studies performed in high-incidence areas such as Japan and China demonstrated a prevalence of CAG of between 33-84% (20,22,23)

Studies exploring the risk of progressing from CAG to gastric adenocarcinoma report a range between 0-10% with an annual incidence (person-year) of less than 1% (range 0-1.2%). This is regardless of whether the study population is from a high or low-risk area (13,24). This is roughly comparable to other pre-malignant conditions of the digestive tract such as Barrett's oesophagus, and colonic adenomatous polyps, where there are established guidelines on surveillance. A Swedish observational, population-based, cohort study, reviewing biopsy samples of 405,172 patients from 1979 to 2011, demonstrated that 1 in 50 patients with GA would develop gastric adenocarcinoma within 20 years (An annual risk of progression of 0.1%) (15). A second Dutch study exploring the follow-up data on 22,365 patients diagnosed with CAG found the overall annual incidence for the development of gastric cancer in patients with GA was 0.1% (25). This increased to 0.25% for GIM, 0.6% for low-grade dysplasia (LGD), and 6% for high-grade dysplasia (HGD) within 5 years after diagnosis. A recent systematic review found that the annual incidence in most studies varied from 0.1% to 0.5%, but a pooled analysis was not undertaken as there was significant heterogeneity between studies ( $I^2$  statistic of 94%)(13). This is partly explained by the poor quality of evidence in this systematic review derived from small cohorts of patients from single centres.

Utilising endoscopic grading, Japanese investigators found the cumulative 5-year incidence of gastric adenocarcinoma to be 0.7% in those with no or mild GA upon endoscopic assessment, 1.9% with GA and 10% in severe endoscopic GA (26).

### **Gastric intestinal metaplasia (GIM)**

Gastric intestinal metaplasia (GIM) is a common finding in studies of patients undergoing diagnostic upper gastrointestinal endoscopy in particular in those with a current or past *H. pylori* infection. GIM prevalence also increases with *H. pylori* infection, patient age, smokers and also with a first-degree relative with gastric cancer. The overall prevalence of GIM in those undergoing routine endoscopy varies from 13.8% to 19% in Europe (27,28). It is important to point out that the European population is not uniformly representative of that in the UK. For example the population studied by Olmez et al are from a high prevalence area of Eastern Turkey. A Dutch study found GIM to be present in 25.3% of patients undergoing endoscopy

for dyspepsia (29). The prevalence in those infected with *H. pylori* was 33.9% compared to 15.2% of those who were not infected. This study also noted that GIM was present in 55% of patients with a gastric ulcer and 100% of patients with intestinal type gastric adenocarcinoma. A multicentre European study found the prevalence of GIM to be 31.4% in patients infected with *H. pylori* (30). In high-incidence areas such as Japan and China the prevalence of GIM in *H. pylori* infected individuals were 37% and 29.3% respectively (31). GIM was found in only 2% of those not infected with *H. pylori*. (15,32).

There is an increased risk of gastric adenocarcinoma in those found to have GIM. 1 in 39 patients with GIM develop gastric adenocarcinoma within 20 years (15), with similar rates found by *De Vries et al* with an annual incidence of cancer of 0.25% at 5 years (25). A meta-analysis carried out by *Zullo et al* in 2000 found that the risk of gastric adenocarcinoma progression in those with GIM ranged from 0-10% with this range thought to be due to differing study sample sizes and follow-up periods (32). Similarly, a systematic review by Spence et al found the annual incidence to range in most studies from 0.15 to 0.4% (13).

The risk of gastric adenocarcinoma varies with the type and extent of GIM. There are three histological types of GIM with type I or 'intestinal' being termed "complete IM" and types II and III or 'colonic' termed "incomplete IM". "Incomplete IM" has been suggested to carry an increased cancer risk over "complete IM" (32–34). A Portuguese study demonstrated that 31% and 6.9% of those with "incomplete IM" developed LGD and HGD, respectively compared to only 8% of those with "complete IM" developing LGD only (35). Therefore, histological subtyping may have a role in establishing gastric cancer risk although it should be noted that only a minority of patients with invasive gastric cancer seem to have incomplete IM. Additionally, it should be noted that the traditional diagnosis of "complete IM" or "incomplete IM" is made using enzyme-histochemical staining methods that are highly dependent on the individual evaluating them and as such are not reproducible. Therefore, the GDG did not consider histological sub-typing for the guidelines.

The extent of the distribution of GIM appears to be of key importance. There are four patterns of GIM distribution that have been described (36). The first, "Focal" GIM consists of scattered foci, mostly in the lesser curvature and incisura. The second, "Antrum-predominant" GIM, involves most of the antrum and incisura angularis. These two patterns with less extensive involvement of the gastric mucosa consist almost exclusively of complete type IM. The third, "Magenstraße" GIM spreads throughout the lesser curvature from the cardia to the pylorus, also involving the greater curvature of the pre-pyloric antrum. Fourthly, "Diffuse" GIM involves the entire gastric mucosa, with the exception of the fundic areas. These more extensive types had a greater predominance of "incomplete" GIM.

Several studies have demonstrated that more extensive GIM correlates with increased gastric adenocarcinoma risk (32,36–38). Of note, a Columbian study found that when compared to focal or antral-predominant GIM, those with Magenstraße GIM had a 5.7-fold increased risk of gastric adenocarcinoma, whilst those with a diffuse pattern (antrum and gastric body) had a 12.2-fold increased risk. Alongside this, an Italian study demonstrated that a >20% extension of GIM identified those at increased risk (32). A Japanese study found the cumulative 5-year incidence of gastric adenocarcinoma to be 1.5% in those without GIM, compared to 5.3% in those with GIM in the antrum only and 9.8% in those with GIM in the antrum and corpus (26).

Unlike the OLGA Staging System, the OLGIM (Operative Link for Gastric Intestinal Metaplasia) Staging System, using the presence of GIM, has proven to be a reproducible

marker of risk with high interobserver agreement and strong association with OLGA stage (39,40). The GDG did not agree that OLGIM should be routinely used in clinical practice, although it has practical applicability in research settings.

Intestinal metaplasia of the gastric cardia has been reported to vary from 5% to 25% in those having endoscopy(41,42) and may confer an increased risk of dysplasia and cancer although the incidence is not clear. Sharma and colleagues found 1/76 patients with prevalent low grade dysplasia in cardia intestinal metaplasia (CIM) as defined as that just below the gastro-oesophageal junction compared to 20/177 having low and high grade dysplasia with short segment Barretts Oesophagus (Less then 3cm)(43).

### Gastric dysplasia

The endoscopic prevalence of gastric dysplasia varies from 0.5% to 3.7% in Western countries and 9% to 20% in areas with a high incidence of gastric adenocarcinoma (44–47). The identification of gastric dysplasia should also alert the endoscopist to the possibility of synchronous gastric cancer. Studies have demonstrated the incidence of synchronous gastric adenocarcinoma in those with gastric dysplasia to be up to up to 30% (44).

A review of the natural history of gastric dysplasia demonstrated that patients with HGD had a rate of malignant progression or synchronous malignant lesions of 60-85% over a median interval period of 4 to 48 months (44). In the work by *Song et al* their observational study found that 1 in 19 patients with dysplasia progressed to gastric adenocarcinoma within 20 years, although no differentiation was made between those with LGD or HGD (15). *De Vries et al* noted the annual incidence of gastric cancer was 6% in patients with HGD within 5 years (25). Of note, it is difficult on histopathology to distinguish between HGD and gastric adenocarcinoma from small biopsy samples.

The risk of progression in individuals with LGD is less clear. There is evidence to show that LGD will regress in 38-75% of patients and persists in 19-50%. In the LGD lesions that persist, the risk of malignant progression ranges from 0-23% in the published literature over 10-48 months (44). *De Vries et al* reported that the annual incidence of gastric adenocarcinoma risk in those with LGD was 0.6% within 5 years after diagnosis (25).

Visible LGD following resection is upstaged in 25% to 35% of lesions, including those less than 1 cm, with an adenocarcinoma rate of 6.9% (44). We have therefore suggested that the risk of prevalent HGD or gastric adenocarcinoma is greater in visible LGD. Although there is uncertainty with regards to the natural history of non-visible LGD, the evidence suggests that there is an increased rate of progression, but the magnitude is currently unclear.

A summary of the risks of gastric cancer can be seen in table 3.

**Table 3: The risk of cancer for patients with gastric atrophy and intestinal metaplasia**

	5 year incidence GC (%)	Annual incidence (%)
<b>All GA</b>	1.9	0.1 – 0.5
<b>Mild GA</b>	0.7	
<b>Severe GA</b>	10	
<b>All GIM</b>		0.15 – 0.4 0.25
<b>Antral GIM</b>	5.3	
<b>Antral &amp; corpus GIM</b>	9.8	

	4 to 48 month interval	
<b>LGD</b>	0 – 23	0.6
<b>HGD</b>	60 - 85	6

### **6.1.2 Risk factors for gastric adenocarcinoma**

*Are there groups of individuals (without known pre-cancerous lesions) known to be at increased risk of gastric adenocarcinoma ?*

**There are sub-groups of individuals (other than those with *H. pylori* infection) who have an increased risk of gastric adenocarcinoma. The strongest risk factors include family history of gastric adenocarcinoma and serologically confirmed pernicious anaemia with gastric atrophy. Additional risk factors include non-White origin, history of gastric surgery for benign disease longer than 15 years, age older than 45 years, male sex, high salt intake, and smoking (Evidence level: low quality; Level of agreement: 93%)**

There are several factors that increase the risk of developing malignant lesions of the stomach, which should be taken into account when considering screening on an individual basis. These risk factors might help develop larger scale screening programmes in the future and relate to multiple sub-categories including patient demographics, epidemiological factors, as well as personal, past medical, social, and family history. Unfortunately, the grade of evidence on the link between risk factors and gastric cancer development is low, as this comes almost universally from retrospective or observational studies, including meta-analyses from these studies. The working group has analysed the evidence related to 11 risk factors based on the available literature.

Family history appears to be one of the strongest risk factors. Three case-control studies (from Japan, Poland and South Korea) for a total of 1,024 gastric cancer cases showed that the odds ratio (OR) for gastric adenocarcinoma in first-degree relatives of patients with gastric adenocarcinoma ranged from 2.3 to 3.5 (48–50). In another US-population case control study, the risk of gastric adenocarcinoma was higher in subjects reporting 2 or more family members with gastric adenocarcinoma (OR 5 to 12.1, 95% CI 1.35–108.5). Two additional studies have suggested that the risk is higher and the age of onset lower in those with a family history of early-onset (<50 years) gastric adenocarcinoma (51,52). In addition, a retrospective cohort study on US Veterans with GIM indicated that a family history of gastric adenocarcinoma was associated with a hazard ratio (HR) of 3.8 (95% CI 1.5-9.7) for gastric adenocarcinoma development (53). In keeping with this evidence, monozygotic and dizygotic twins of individuals with gastric adenocarcinoma have 9.9 and 6.6-fold higher risk of gastric adenocarcinoma respectively, compared to twins of subjects without gastric adenocarcinoma (54). It is important to consider that familial aggregation occurs in approximately 10% of cases, which in low incidence countries of gastric adenocarcinoma likely relates to heritable pathogenic mutations. However, truly hereditary cases are deemed to account for approximately 1-3% of all gastric adenocarcinoma cases and include three main subgroups: hereditary diffuse gastric cancer (HDGC), familial intestinal gastric cancer (FIGC) and other single-gene syndromes associated with a possible increased risk of gastric adenocarcinoma (55). The latter include gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)(56,57), Li-Fraumeni syndrome, familial adenomatous polyposis (FAP), Peutz-Jeghers syndrome, juvenile polyposis, Cowden’s syndrome/PTHS, and Lynch syndrome(58). More than 90% of individuals with a PTEN pathogenic variant who underwent at least one



upper or lower endoscopy were found to have polyps(59). Histologic findings varied, ranging from ganglioneuromatous polyps, hamartomatous polyps, and juvenile polyps to adenomatous polyps. The association of gastric cancer with familial adenomatous polyposis (FAP) is mainly based on case reports and thus remains weak.

Although this guideline does not cover management of hereditary gastric cancer it is important to know how to take an appropriate family history, in order to suspect familial gastric cancer and know when to refer for genetic counselling. Outside the context of specialised genetic counselling clinic, where the three-generation comprehensive pedigree is recommended, in standard clinical practice it is recognised that it is sufficient to focus on first-degree (parents, children and siblings) and second degree relatives (grandparents, aunts/uncles, nieces/nephews, grandchildren and half-siblings) in order to assess the empiric individual risk profile (60). Affected relatives should be from the same lineage (Maternal or paternal) and be first degree relatives of each other. The age of diagnosis, the histological type of gastric cancer (if possible) and the occurrence of GI polyps and other cancers, including colorectal, ovarian, breast and pancreatic cancer should be recorded. Criteria for referring to genetic services are outlined in Table 4 (61,62). It is important to note that the criteria for a clinical diagnosis of HDGC have been slightly relaxed in the more recent updated clinical guidelines and that a history of breast cancer is particularly important for a clinical suspicion of familial gastric cancer important as there is clustering between gastric and breast cancers, not only in HDGC (Lobular type) but also in other familial cancer syndromes, including Peutz-Jeghers and Cowden(61,63). Individuals that fulfil the family history criteria for suspected familial gastric cancer in the absence of a mutation identified could be considered for endoscopic surveillance. Ideally this should be offered as part of a clinical trial as there are no validated surveillance protocols in this group of individuals. In the absence of evidence we would suggest 3 yearly endoscopy with high-definition endoscopy and image enhancement as a possible protocol. Details of genetic centres in the UK can be found on the British Society of Genetic Medicine website <https://www.bsgm.org.uk>.

**Table 4:Criteria for referring to genetic services**

<b>Suspected familial gastric cancer</b>
1. Gastric cancer in one family member before age 40, or
2. Gastric cancer in two 1 <sup>st</sup> / 2 <sup>nd</sup> degree relatives with one diagnosis before age 50*, or
3. Gastric cancer in three 1 <sup>st</sup> / 2 <sup>nd</sup> degree relatives independent of age*, or
<b>Suspected Hereditary Diffuse Gastric Cancer</b>
1. One case of diffuse gastric cancer before age 40, or
2. Two cases of gastric cancer regardless of age in two 1 <sup>st</sup> / 2 <sup>nd</sup> degree relatives, at least one confirmed diffuse gastric cancer*, or
3. Personal and family history of diffuse gastric and lobular breast cancers, with one diagnosis before age 50
4. A personal or family history of cleft lip/palate in a patient with diffuse gastric cancer
5. In situ signet ring cells or pagetoid spread on gastric biopsies

\* in order to account for significant family history, the affected relatives need to be within the same side of the family (maternal or paternal)

There are multiple genetic polymorphisms that have been shown to be associated with an increased risk of gastric cancer, in particular related to inflammatory response genes such as interleukins, interleukin receptors, and tumour necrosis factor (64). There currently is insufficient evidence to recommend routine DNA genotyping to inform clinical decisions

outside cases that meet the criteria for familial gastric cancer (55). A detailed discussion on this topic is beyond the scope of this guideline.

Pernicious anaemia is another strong risk factor for gastric adenocarcinoma development. A systematic review by Vannella and co-workers found that the pooled incidence of gastric adenocarcinoma in patients with pernicious anaemia is 0.27% per year with a relative risk (RR) of 6.8 (95% CI 2.6-18.1) (65). A more recent population-based case-control study on 1,138,390 cancer cases compared with 100,000 matched controls found that in patients with pernicious anaemia the ORs for gastric adenocarcinoma and gastric NETs were 2.18 (95% CI 1.94-2.45) and 11.4 (95% CI 8.9-14.7), respectively (66). Since these were unverified pernicious anaemia cases, this was likely a marked underestimate of the cancer risk in true pernicious anaemia patients. Substantiating a diagnosis of pernicious anaemia however can be challenging. Megaloblastic anaemia and vitamin B12 deficiency can depend on a multitude of clinical conditions and the diagnostic accuracy of auto-antibodies is low (low specificity for anti-parietal cell antibodies and low sensitivity for anti-intrinsic factor antibodies) (67,68). Therefore, in order to stratify cancer risk, it is essential that histopathological evidence of auto-immune atrophic gastritis corroborates the serological diagnosis.

It has long been suggested that a previous history of gastric surgery for benign disease is a risk factor for gastric adenocarcinoma. Three early retrospective cohort studies have shown an increased gastric adenocarcinoma risk in individuals carrying a gastric stump from previous surgery for non-malignant disease compared to the general population (69–71), while one case-control study did not reach similar conclusions (72). The discrepancy may be resolved by a more recent and large retrospective study which found that the risk of gastric adenocarcinoma in a gastric stump only increases after 30 years from gastric surgery with an SIR of 2.29 (95% CI 1.38-3.57) (73). Hence, it is reasonable to conclude that the risk of gastric adenocarcinoma arising in the gastric stump is unlikely to be significantly increased within the first 15 years post-surgery. However, it should be noted that these data may be confounded by *H. pylori* status.

Ethnicity is strongly related to the risk of gastric adenocarcinoma. Several retrospective cohort studies conducted in US and UK populations showed that Whites appear to have a lower risk compared to Asians (2.1 fold higher incidence), Blacks (1.7 fold higher incidence) and Hispanic-Latinos (1.7 fold higher incidence) (74–78). Among Asians, Chinese and Koreans appear to have the highest risk of a pre-malignant stomach with an OR of 4.77 (95% CI 4.54–5.01) and 7.39 (95% CI 7.06–7.73), respectively (21). These differences are likely to be, at least in part, explained by differences in *H. pylori* prevalence, *H. pylori* subtypes, and host genotypes.

There is evidence that older age is a risk factor for developing gastric adenocarcinoma reflecting the duration of *H. pylori* gastritis. Different studies report different age groups to study this association, e.g. 45, 50 or 75 years of age, hence it is difficult to identify an age cut-off to guide clinical decisions (25,79,80). However, three studies have shown that age more than 45 years is associated with a significant OR between 1.92 and 3.1 for progression of premalignant stomach to gastric adenocarcinoma (25,81,82). Hence, it is reasonable to consider for potential screening strategies 45 years of age as a useful threshold.

Males appear to be at increased risk of gastric adenocarcinoma compared to females. Two cohort and one case control studies showed different strengths of this association with a relative incidence in male compared to female ranging from 1.3 to 3 fold higher (74,79). This does not

apply to cases of gastric adenocarcinoma occurring before the age of 40 years, likely due to the domineering genetic background responsible for early-onset cancer (55,83).

Smoking seems to be an additional risk factor for gastric adenocarcinoma development, particularly, but not limited to, gastric cardia adenocarcinoma. Smoking appears to be responsible for 18% of gastric adenocarcinoma risk (84) and this relates to an increase in the risk by 1.45-2 fold according to different studies (85,86). However, a recent meta-analysis only showed a trend for increased risk of gastric adenocarcinoma development in current smokers which did not meet statistical significance (OR 1.49; 95% CI 0.99-2.225) (87).

Other risk factors that have been studied and were assessed by the working group include alcohol consumption, diabetes, obesity, and PPI use (88–90). For these factors the available evidence is conflicting or does not show a clear relation to the risk of gastric adenocarcinoma development. In particular for obesity there is sufficient evidence to conclude that this is associated to the risk of cardia cancer, but not non-cardia gastric cancer (91). There have been a number of recent studies investigating the association of PPIs, and gastric cancer. A study by Cheung et al assessing patients who were treated for *Helicobacter pylori*, demonstrated an association between PPI use and gastric cancer in a population from Hong Kong. PPI use was associated with a 2.44 fold increase in cancer. No increase was detected in H2 antagonists and most cancers were non-cardia. There were significant flaws in this study. Most importantly the PPI group were 10 years older on average than the non-PPI group and as gastric cancer increases with age it would be expected that the risk would be greater in this group. Similarly a Swedish study showed a similar increase in gastric cancer in PPI users with the greatest risk in younger men. No difference was however found in a US study looking at pantoprazole. It can be concluded that although there is an association between PPI use and gastric cancer, no causal link has been proven. Furthermore, this association may be limited to specific populations and limited to patients who have had *H. pylori* eradication (92–94). We make reference to a BSG position statement (95) which recommends that if acid suppression is required after *H. pylori* eradication, H2-antagonists should be used first and if these are ineffective PPIs can be initiated with the above information being shared with the patient. In other patients there is no evidence at the moment to advise against the use of PPIs first line for short term use. Prolonged use should be accompanied with an explanation of the evidence for possible risks as described above.

### **6.1.3 *H. pylori* and gastric cancer**

*Who should be tested and treated for H. pylori to reduce the risk of gastric cancer?*

**We do not recommend testing and treating for *H. pylori* to reduce the incidence of gastric cancer in low incidence areas such as the UK** (Evidence level: high quality; Grade of recommendation: high; Level of agreement: 100%)

Several studies in rodents support the hypothesis that eradication of *H. pylori* infection prevents the subsequent development of gastric adenocarcinoma (96,97). However, the benefits were reduced in these animal models when infection was eradicated at later stages in the natural history of the disease. Multiple human cohort studies as well as randomised clinical trials have now been performed to assess whether testing for *H. pylori* in the asymptomatic population and its subsequent eradication in infected subjects reduces the subsequent incidence of gastric

cancer. In turn, these studies have been subjected to systematic reviews and meta-analyses by at least three independent research groups. The conclusions were that searching for and eradicating *H. pylori* reduced the incidence of gastric adenocarcinoma in healthy asymptomatic infected individuals, with the number of patients needed to treat was as low as 15 for Chinese men, but as high as 245 for US women (98,99) (100). The benefits of eradication varied with baseline gastric cancer incidence, but did not differ with study design, sex, or follow-up period baseline risk (101).

Thus, there is compelling evidence that *H. pylori* eradication is effective at reducing the subsequent risk of gastric adenocarcinoma development. In areas of low to moderate gastric adenocarcinoma incidence such as the UK however, it has been suggested that this is not a cost-effective strategy. However, as recently argued by *O'Connor et al* (102), there may be additional benefits associated with *H. pylori* eradication such as a reduction in peptic ulcer disease and dyspepsia and these have not been considered in all the proposed economic models. Other potential consequences of widespread *H. pylori* eradication therapy should also be considered when considering the risk benefit ratio of such a strategy. These include the potential emergence of antibiotic resistant strains of the organism and treatment-associated side effects some of which, although rare, can be serious, such as *Clostridium difficile* infection (102).

Therefore, although *H. pylori* eradication is a feasible, efficacious, and potentially cost-effective method (at least in some populations) for reducing the risk of subsequent gastric adenocarcinoma development, its use has not yet been adopted anywhere in the world. The final results of a very large Chinese trial involving more than 180,000 participants will be available within the next few years and its results may influence future public health policy in this area, particularly in East Asian countries (103). However, at present, in areas of relatively low gastric cancer incidence such as the UK, we cannot currently recommend population testing and treating for *H. pylori* as a means for preventing subsequent gastric cancer development

*Does eradication of H. pylori prevent progression to cancer?*

**We recommend *H. pylori* eradication to reduce the risk of gastric adenocarcinoma development in patients who have *H. pylori*-associated gastric atrophy** (Evidence level: High quality; Grade of recommendation: high; Level of agreement: 100%)

**We suggest that *H. pylori* eradication may be of some benefit to reduce the risk of developing gastric adenocarcinoma in those who already have *H. pylori*-associated gastric intestinal metaplasia, dysplasia, or cancer.** (Evidence level: High quality; Grade of recommendation: weak; Level of agreement: 100%)

Although there is good evidence that *H. pylori* eradication reduces the subsequent risk of gastric adenocarcinoma development, it has been hypothesised that there may be a "point of no return" in the precancerous cascade. This question has been assessed in multiple studies and has been the topic of two recent independent systematic reviews and meta-analyses and most recently a large randomised controlled trial.

*Chen et al* performed a meta-analysis of ten studies from eight randomised controlled trials with a total of 7,955 participants (104). These authors divided participants into subgroups based on their baseline diagnoses comparing a group without GIM (normal, non-atrophic gastritis,

GA) and a group with GIM (GIM, or dysplasia). *H. pylori* treatment compared with controls significantly reduced the risk of gastric cancer, with a pooled RR of 0.64 (95% CI, 0.48-0.85). Subgroup analysis for patients with non-atrophic gastritis and GA yielded similar results (RR = 0.25, 95% CI, 0.08-0.81). However, this difference was not observed in patients with GIM or dysplasia (RR = 0.88; 95% CI, 0.59-1.31). The authors concluded that *H. pylori* treatment no longer decreased the risk of gastric adenocarcinoma development once patients had developed GIM or dysplasia,.

Rokkas et al., 2017 recently published a second independent meta-analysis on this topic (105). They analysed 26 studies (10 randomised controlled trials and 16 cohort studies) and included 52,363 subjects. The risk of gastric adenocarcinoma among patients in whom *H. pylori* had been successfully eradicated was significantly lower than that among controls (pooled RRs [95% CI] 0.56 [0.48-0.66],  $Z = -7.27$ ,  $P = 0.00001$ ). In patients with precancerous lesions however, subgroup analyses showed that patients with non-atrophic or GA benefitted from *H. pylori* eradication to decrease the risk of gastric cancer development, whereas those with GIM or dysplasia did not. In contrast to these data, a recent large randomised placebo-controlled trial which demonstrated a significant reduction in metachronous gastric adenocarcinoma rates after endoscopic resection of intramucosal cancer and HGD in the *H. pylori* eradication group (13.4 % vs 7.9%;  $P = 0.03$ ) (106). Furthermore, there appeared to be a reversal in the severity of both GA and GIM in the corpus, but not in the antrum.

Current high-quality data therefore suggest that while eradication of *H. pylori* reduces subsequent gastric adenocarcinoma risk in patients who have non-atrophic or GA, these benefits are not consistently maintained in patients who have developed GIM, dysplasia or cancer. The published meta-analyses did not however address whether the histological type, severity, or location of GIM or dysplasia influence this response to treatment. Although early data do not consistently support the use of *H. pylori* eradication in patients who already have established intestinal metaplasia, dysplasia, or cancer, the aforementioned RCT provides evidence to treat those with established cancer or HGD.

Although most of the published evidence is from the Far East, there is no compelling evidence to suggest that the fundamental process of gastric carcinogenesis differs according to geographical location. The published evidence suggests that *H. pylori* eradication appears to prevent gastric cancer development in some patients who have atrophic gastritis. Despite the lack of studies from the UK and Europe, *H. pylori* eradication is likely to benefit some European patients who have atrophic gastritis and has a very low risk of causing serious adverse events. Further studies in European populations are however needed to expand the pool of evidence that will influence this recommendation when these guidelines are revised.

The success of a *H. pylori* eradication strategy in order to try to prevent cancer development in patients who have premalignant gastric conditions will obviously be influenced by the success rate of the actual bacterial eradication regime that is used. The choice of eradication regime is beyond the scope of these guidelines, but its efficacy should be monitored. Regimes other than classical triple therapy may need to be employed, particularly in geographical locations where the rates of *H. pylori* antibiotic resistance are known to be high.

In addition to the conventional Correa cascade of gastric carcinogenesis there are other gastric conditions that are potentially associated with an increased risk of gastric cancer development, in particular some gastric polyps (107). Although there is good evidence to suggest that *H. pylori* eradication leads to the regression of gastric hyperplastic polyps, no studies appear to

have analysed whether this influences subsequent gastric adenocarcinoma risk (108–110). Studies on the effects of *H. pylori* eradication in patients with gastric adenomas are too small to draw any valid conclusions (111).

#### **6.1.4 Biomarkers and gastric cancer**

*What biomarkers are useful in the management of these lesions?*

*Can they be applied to population screening, monitoring those at risk, or those with known lesions?*

**Measurement of serum pepsinogen I and serum pepsinogen I/II ratio alone or in combination with *H. pylori* serology, and/or Gastrin -17 can identify individuals with extensive atrophic gastritis.** (Evidence level: Low quality; Grade of recommendation: weak; Level of agreement: 93%)

**We do not recommend the use of biomarkers as a screening tool in areas with a low incidence of gastric adenocarcinoma, such as the UK.** (Evidence level: Low quality; Grade of recommendation: weak; Level of agreement: 100%)

#### **Chronic atrophic gastritis (CAG), dysplasia and gastric adenocarcinoma**

Pepsinogen I (PGI) is mainly secreted by chief and mucous neck cells in the fundic mucosa whilst pepsinogen II (PGII) is also secreted by pyloric and duodenal Brunner's glands. Approximately 1% of pepsinogens are found in the serum with their serum level accepted as a marker for the morphological and functional status of the gastric mucosa (10,112,113). Serum PGI and PGII levels both increase in gastric mucosal inflammation; however, as GA develops and specialised cells are lost, PGI and PGII levels decrease, usually more marked in PGI, resulting in low serum PGI and a low PGI/II ratio (114).

The combined use of serum PGI and PGI/II ratio measurements are an accepted useful biomarker for pre and malignant gastric lesions (112). Studies exploring their use as a population screening tool, where those with a positive pepsinogen result progress to endoscopic examination, have been demonstrated to be acceptable in screening asymptomatic populations with a good uptake of invitations for endoscopy, over 60%, in those with a positive pepsinogen result (115,116).

#### **Biomarker detection of CAG, dysplasia and gastric cancer**

There are numerous studies across many different countries and populations that have explored the use of serum pepsinogen testing for detection of CAG, dysplasia, and gastric adenocarcinoma. The majority of these studies are from countries with a higher incidence of these lesions than the UK. With regards to countries with an incidence of gastric adenocarcinoma similar to the UK, a study by *Broutet et al* in 2003 assessed serum pepsinogen testing across 14 European nations and determined that PGI/II ratio may be of use as a screening test (112,117,118). However, in the majority of studies the values used to define a positive pepsinogen test result and the study outcomes are reflective of populations that ultimately differ from the UK population. Additionally, many of these studies use differing cut-off values that make comparison difficult. However, the most frequently used values for these studies is a PGI <70 ng/ml and a PGI/II ratio  $\leq 3$  (112). Values can be affected by

laboratory methodologies and population settings and therefore may require adjustment if they were to be applied to the UK population.

A recent meta-analysis by *Huang et al* found that serum pepsinogen testing had a sensitivity and specificity of 69% and 73% for gastric cancer diagnosis and 69% and 88% for CAG diagnosis, respectively (112). This analysis included a study population of over 30,000 individuals, across 13 different countries and diagnosis confirmed with gastroscopy and biopsy. This is comparable to the 2004 meta-analysis performed by *Dinis-Ribeiro et al*, using a cut-off of PGI <50 and PGI/II ratio  $\leq 3$  for dysplasia detection, where sensitivity and specificity was 65% and 74-85% respectively (117). This included a study population of approximately 300,000 patients. Finally, in a 2014 meta-analysis by *Terasawa et al* a study population of approximately 32,000 patients where individuals were prospectively followed up between 3.9-14 years, found that a positive pepsinogen test had a sensitivity of 57% and specificity of 76% for the development of gastric adenocarcinoma (119).

### **Biomarker population screening**

Whilst pepsinogen testing has been demonstrated as a useful tool for population screening in high-risk areas, its use in low-risk areas such as the UK has not been explored (116,119,120). In particular one must address whether the moderately effective sensitivities and specificities of pepsinogen testing are cost-effective for screening an asymptomatic population where the incidence of the disease is low. A 2015 study by *Yeh et al* utilised a mathematical simulation model to calculate the cost effectiveness of population screening strategies based on biomarker and endoscopic technologies in the low-risk USA population (Defined as an age-standardised rate, ASR <10 per 100,000). This study found that although one time serum pepsinogen testing at the age of 50 could prevent one in four gastric adenocarcinoma among men it was not of high value in improving cancer outcomes. However, targeting the high-risk group of male smokers over 50 years old could be a cost-effective way to reduce mortality of gastric adenocarcinoma (113). This screening model requires further exploration.

*H. pylori* serology has been studied extensively both as a population screening tool alone, as part of a “test and treat” strategy, and in conjunction with pepsinogen testing. Whilst its use as a screening tool or in the “test and treat” strategy may have advantages in high-incidence areas (defined as an age-standardised rate, ASR >20 per 100,000), the disadvantages including low specificity and antibiotic resistance in low-risk populations render its use redundant (121). The use of *H. pylori* serology in combination with pepsinogen is more accurate. In particular the finding of negative serum anti-*H. pylori* (Hp) IgG antibody and positive pepsinogen measurements suggests extensive GA and thus these individuals are at highest risk of progression to cancer (10,121). The ABCD method for the detection of high gastric adenocarcinoma risk individuals has been extensively investigated in high-risk populations. This method categorises patients tested for *H. pylori* serology (HP) and the ratios of serum PGI and PGII (sPG) into low risk (A: HP -, sPG-), moderate risk (B: HP+ and sPG-), and high risk (C: HP+ and sPG+; D: HP-, sPG+). Although in a 20 year prospective study the hazard ratios for developing gastric adenocarcinoma were 15 for group D when compared to group A (122), further evidence is required to support the use of these approaches in a low risk population.

Gastropanel® combines PGI, PGII, gastrin-17 and *H. pylori* serology. A recent meta-analysis assessed the performance of this serum panel test for the diagnosis of CAG in 4241 subjects. The sensitivity for CAG was 74.7% (95% confidence interval (CI), 62.0-84.3) and the specificity was 95.6% (95%CI, 92.6-97.4). With a prevalence of CAG of 27% (median

prevalence across the studies), the negative predictive value was 91% and positive predictive value was 86% (123). Thus, although studies to date have shown promise, there is little in the way of evidence to support its use with conflicting data on its efficacy (124–126).

Finally, note is made of studies exploring the detection of volatile organic compounds in exhaled breath that are associated with the detection of gastric adenocarcinoma (127).

## **6.2 Endoscopic diagnosis of pre or early malignant lesions of the stomach**

### **6.2.1 Ensuring high quality endoscopic evaluation**

*Outside the recommendations within the UK guidelines for quality endoscopy are there further processes that are suggested for the detection and diagnosis of pre or early malignant lesions of the stomach? Is a station-based approach beneficial?*

**We recommend patients at higher risk for gastric adenocarcinoma, including gastric atrophy and gastric intestinal metaplasia should undergo a full systematic endoscopy protocol of the stomach with clear photo documentation of gastric regions and pathology. We suggest a minimum examination time of 7 minutes.** (Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 100 %)

An endoscopy needs to be of high quality in order to detect dysplasia and early cancers, particularly in light of post-endoscopy gastric cancer rates of 11.3% (128). Recognising and targeting high-risk patients with GA and GIM may be the most effective means to improve gastric cancer detection, and possibly survival, in the UK. There are three basic principles, which are part of routine practice: cleaning of the gastric mucosa, adequate distention of the gastric wall by air insufflation, and mapping the entire stomach.

Although there is little available evidence on the use of smooth muscle relaxants and mucosal cleaning techniques, the new BSG Position Statement on Quality Standards in Upper Gastrointestinal Endoscopy recommends: ‘Adequate mucosal visualisation should be achieved by a combination of adequate air insufflation, aspiration and the use of mucosal cleansing techniques’ (129). We recommend this guidance is also applied to inspection of GA and GIM.

There is also a paucity of data on the assessment of a complete endoscopic procedure. In particular there are no clinical trials to directly clarify key performance indicators (KPI) or quality assurance (QA) for improving gastric cancer detection, or studies exploring the outcomes of systematic screening protocols for the stomach. The ESGE performance measures for upper GI endoscopy have suggested the inspection of the oesophagus, stomach and duodenum should last at least 7 minutes from intubation to extubation (130). This statement was based on a retrospective cohort study by *Teh et al* which aimed to determine the diagnostic yield for early neoplastic lesions in the stomach (131). After evaluating 837 endoscopies of symptomatic patients with no history of gastric cancer, they found that a ‘slow’ endoscopist (> 7 minute examination) was twice as likely to detect high risk gastric lesions, defined as biopsy evidence of GA, GIM, gastric dysplasia, or cancer and three times as likely to detect a case of dysplasia or cancer compared to a ‘fast’ endoscopist (< 7 minute examination) (131,132).

Photo-documentation might be an indirect quality indicator. Endoscopists with longer procedure times, who take more than 4 pictures, detect more pathology (132). The ESGE has recommended 5 areas in the stomach should be photo-documented including the cardia and



fundus in inversion, corpus in forward view including lesser curvature, corpus in retroflex view including greater curvature, angulus in partial inversion, and antrum. Images may be utilised in case discussions, patient management and compared to histology to aid learning.

In Japan, a systematic screening protocol for the upper GI tract has been developed, although this is considered too complex for routine clinical practice (133). This was revised by the Japanese Society of Gastroenterological Cancer Screening (JSGCS) to a simplified, but still elaborate protocol (134). Yao has more recently simplified this further to propose as a minimum required quality standard a “systematic screening protocol for the stomach (SSS)” (135). This is a station-based approach whereby each area of the stomach is viewed and photographed in either a clockwise or counter-clockwise manner. The 22 pictures are arranged according to the order of the procedure. Additional pictures are taken of lesions (Figure 2). A recent study from China found that training including a systematic inspection protocol with 20 photos increased the detection of early gastric cancer from 0.2 to 2.3 % (136)

An e-learning module has been developed to teach endoscopists how to diagnose early gastric cancer based on the characterisation of Gastritis-like lesions, Ulcerative lesions, and Polypoid lesions, the so-called GUP system (137,138). The GUP system has been evaluated in a randomised controlled trial involving 332 endoscopists in 27 countries with higher mean improvement rate in the e-learning group than that of the non e-learning group (138). A further study clearly demonstrated the efficacy of an e-learning system in improving endoscopists’ capabilities to diagnose early gastric cancer using Magnification-Narrow Band Imaging (M-NBI) (139). Such validated training modules may be incorporated into any future quality improvement programs aimed at improving gastric cancer diagnosis.

We recommend that when either GA or GIM are recognised on WLE, a full systematic endoscopic examination of the whole stomach is performed, taking no less than 7 minutes, with full photo-documentation of antrum, pylorus, incisura, lesser curve, greater curve, fundus, and cardia. For patients without known risk factors for gastric cancer, we recommend a standardised high-quality endoscopy as defined in the UK Quality in Upper Gastrointestinal position statement.

### **6.2.2 Optical endoscopic diagnosis of the pre or early malignant stomach**

*How does one identify pre or early malignant lesions and ensure accurate documentation when reporting? Are there mucosal features that identify these lesions (including recognizing the atrophic border)?*

*What histopathological and imaging modalities are suggested for the staging of glandular pre- and early gastric malignant lesions of the stomach?*

**Gastric atrophy and gastric intestinal metaplasia may be detectable by white light endoscopy, however the accuracy is poor. Therefore, we do not recommend establishing a diagnosis or risk-stratification using white light endoscopy alone.** (Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 93%)

**We recommend image-enhanced endoscopy is the best imaging modality to accurately detect and risk-stratify gastric atrophy and gastric intestinal metaplasia** (Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 100%)

**We recommend that endoscopic appearances on white light endoscopy suggestive of atrophy or gastric intestinal metaplasia require escalation to high resolution, image-enhanced endoscopy and, where available, magnification endoscopy** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)

**We recommend that the location and extent of gastric atrophy and gastric intestinal metaplasia should be clearly documented with photo-evidence. Endoscopic grading should be documented as distal gastric (affecting antrum or incisura - low risk) or proximal gastric (affecting the corpus with or without the antrum and incisura - high risk).** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 93%)

**We recommend that endoscopic appearances on white light endoscopy of gastric dysplasia and early gastric cancer (differences in colour, loss of vascularity, slight elevation or depression, nodularity, thickening, and abnormal convergence or flattening of folds) require escalation to image-enhanced endoscopy and, where available, magnification endoscopy** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)

**We recommend image-enhanced endoscopy is the best imaging modality to accurately diagnose and stage gastric dysplasia and early gastric cancer** (Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 100%)

Endoscopic detection and staging of GA, GIM and dysplasia is achievable with high resolution WLE but improved with image enhancement and magnification endoscopy. The white light, image enhanced and magnification appearances of the different mucosal patterns within the stomach are described below, covering the normal antrum and corpus as well as GA and GIM.

## **Normal gastric appearances**

### *White light endoscopy*

Typically, the surface of the normal corpus, when the stomach is empty and not distended, is almost invariably in folds, also called rugae, which vary in size depending upon the degree of insufflation during the endoscopic assessment. In contrast, the surface of the normal fundus and antrum are smooth. The colour of the normal gastric mucosa, as indeed of the whole gastrointestinal tract, is velvety glossy dark rose or red with a regular arrangement of the collecting venules (CV) usually visible as red spidery vessels in the normal corpus (140–143). The presence of these collecting venules is characteristic of a normal stomach without *H. pylori* (sensitivity 93%, specificity 48%) (140,144,145). With current white light, high resolution endoscopes the round ‘pit patterns’ of the corpus and elongated ‘pit patterns’ of the antrum can be seen without magnification or enhancement (Fig 3 Ai & 1Di).

### *Magnification and enhanced endoscopy*

The two key features that characterise the gastric mucosa on magnifying endoscopy include the surface structure and vascular architecture.

Essentially, the corpus mucosa has straight or tubular glands with round ‘crypt openings’ (CO)(146). These dark round pits are surrounded by the lighter coloured marginal crypt epithelia (MCE), then the darker circular sub-epithelial capillary network (SECN). This structure forms the typical foveolar type pattern, where dark areas (capillaries) surround light areas (glands) (147–149). These appearances correspond with the tubular gland structure of the corpus mucosa histologically (Fig 3 Ei, Eii & F). In NBI, the pattern “regular vessels with circular mucosa” is associated with normal histology (accuracy 83%; 95% CI 75%-90%) (150).

In contrast to the corpus, the glands in the antrum are oblique and branching and the dark ‘pit openings’ are grooved. The light coloured ridged or villiform epithelium (MCE) surrounds the dark SECN, which can be seen as coiled vessels (Fig 3 Aii & Aiii). This appearance is termed the ‘groove type pattern’ (147,148). These appearances correspond with the papillary surface structure of the antral mucosa histologically (Fig 3 Bi, Bii & C).

### **Chronic *H. pylori*-gastritis**

There are a number of endoscopic features suggestive of chronic *H. pylori* gastritis including the absence of collecting venules, antral nodularity, enlarged gastric folds, enlargement and destruction of the gastric glands, sticky tenacious adherent mucous, turbid gastric juice, and xanthomas (140–142). Loss of collecting venules and capillary vascular structure was correlated with chronic inflammation and activity. With progression of mucosal atrophy irregular collecting venules become visible (151).

### **Gastric atrophy**

There are four principal endoscopic features of GA described by Nakayama, Uedo and Yao (152–154): pallor, loss of gastric folds, prominence of the vessels, and the atrophic border (Fig 4). Increased visibility of the vascular network showed a sensitivity of 48% and specificity of 87%, while the loss of gastric folds has a sensitivity 67% and specificity of 85% (155).

Long-term cohort studies suggest the Kimura-Takemoto classification is a useful risk stratification assessment tool to predict gastric adenocarcinoma development (26,31,156). Essentially this tool utilises the extent of the atrophic border (the border between the pale atrophy and normal red coloured stomach), to stage the extent of GA (Fig 4). In a cross sectional cluster sampling historical study between the UK and Japan, endoscopic grading was shown to be comparable to histopathology and correctly predict histopathological atrophy with few false negatives (157,158). This work needs further confirmation in a larger setting outside of Japan. The Kimura-Takemoto classification has been simplified to a modified staging system involving antrum only (antral), antrum to incisura (antral dominant), antrum to lesser curve (corpus dominant), and antrum, lesser curve and greater curve (Pan-atrophy). This staging system integrates the Sydney biopsy system discussed later (Fig 5). The GDG agreed that the extent of GA and GIM should be stratified as low risk (Involving the antrum and incisura) or high risk (Involving the corpus and antrum/incisura or corpus alone).

### **Gastric intestinal metaplasia**

#### *White light endoscopy*

GIM typically appears as small grey-white slightly elevated plaques surrounded by mixed patchy pink and pale areas of mucosa causing an irregular uneven surface (Fig 6A). Mottled patchy erythema has also been positively associated with GIM (159). However, diagnosis using standard endoscopy alone (without high resolution or enhanced imaging) is unreliable (160–165) .

### *Magnification & image enhanced endoscopy*

As patches of GIM expand, the straight/tubular glands of the corpus elongate to a ‘groove type pattern’ similar to that of the antrum or villiform pattern of the intestine (Fig 6C & D). Although these changes can easily be distinguished from the normal mucosal background in the corpus both with high resolution white light and enhanced endoscopy, GIM in the antrum is more difficult to characterise as the pre-existent mucosal architecture is quite similar and appears oblique and grooved as well (148,166). Additional features of GIM include the light blue crest (LBC) and the marginal turbid band (MTB) (167) and the white opaque substance (lipid droplets) obscuring the sub-epithelial capillaries(168). The LBC is a fine, blue-white line on the crest of the mucosal surface seen with NBI enhancement and is a highly specific sign of the presence of GIM (166,169) (Fig 6E&F). The MTB is a white turbid band on the mucosal surface. It is suggested that the MTB may represent a sign of early GIM, whereas the LBC appears with progression to severe GIM, although whether this is reproducible remains uncertain.

### **6.2.3 Optimal techniques for the detection and classification of gastric atrophy and gastric intestinal metaplasia**

Most studies have demonstrated improved accuracy of enhanced and magnification imaging in the classification and detection of GA, GIM, dysplasia and cancer, when compared to WLE (150,162,163,165,170,171). An overview of enhanced imaging studies with various modalities and their performance characteristics is provided in Table 5.

**TABLE 5 Endoscopic imaging modalities and performance characteristics for the diagnosis for gastric atrophy and intestinal metaplasia**

Author (year)	Location	No of patients	Study design	Modality	Sensitivity (%)	Specificity (%)	Condition
<b>Dinis-Ribeiro 2003(155,172)</b>	Portugal	136	Prospective	ME MB	76.4	86.6	GIM
<b>Redeen 2003(155)</b>	Sweden	488	Prospective	WLE	67-90 (absence of folds) 48-80 (body visible vessels) 14 (antrum visible vessels)	85-84 (absence of folds) 87-87 (body visible vessels) 91 (antrum visible vessels)	AG
<b>Uedo 2006(166)</b>	Japan	107	Prospective	NBI ME	89	93	GIM
<b>Anagnostopoulos 2007(149)</b>	UK	95	Prospective	WLE ME	90 (body type 4 pattern)	96 (body type 4 pattern)	AG
<b>Bansal 2008(147)</b>	USA	47	Pilot feasibility	NBI	80 (ridge/villous pattern)	100 (ridge/villous pattern)	GIM
<b>Guo 2008(173)</b>	China	53	Prospective	WLE vs CLE	36.88 (WLE) 98.13 (CLE)	91.59 (WLE) 95.33 (CLE)	GIM
<b>Tahara 2009(174)</b>	Japan	106	Prospective	ME NBI (body)	73.3 (type 3 NBI IM) 50 (type 3 NBI AG) 66.7 (WLE open type)	95.6 (type 3 NBI IM) 96.3 (Type 3 NBI AG) 72 (WLE open type)	GIM and AG

<b>Capelle 2010(175)</b>	The Netherlands	43	Prospective	NBI vs WLE	71 (NBI) 51 (WLE)	58 (NBI) 67 (WLE)	GIM
<b>Eshmuratov 2010(170)</b>	Korea	1330	MC Prospective	WLE	61.5 (antrum)- 46.8 (body)	57.7 (antrum)-76.4 (body)	AG
<b>Kawamura 2011(176)</b>	Japan	95 with active DU (n = 24), diffuse-type (n = 24) and intestinal-type (n = 47) EGC	Observational	ME NBI	Types A-1 and A-2 (modified Yagi's A-B classification system) Severe AG-IM seen in the intestinal type EGCs at the lesser curvature (accuracy figures not supplied)		AG and GIM
<b>Rerknimitr 2011(177)</b>	Thailand	38 (I surveillance) 26 (II surveillance)	Prospective	NBI	78.8/91.3 (I/II surveillance) 3 criteria: LBC, VP, and LLC	82.5/89.1 (I/II surveillance) 3 criteria: LBC, VP, and LLC	GIM
<b>Pimentel-Nunes 2012(150)</b>	Europe	85	MC Validation	NBI	89 (tubulo-villous pattern) 48 (LBC)	90 (tubulo-villous pattern) 96 (LBC)	GIM
<b>Dutta 2013(178)</b>	India	200	Randomized prospective crossover	NBI vs WLE	NBI was superior to WLE (accuracy figures not supplied)		AG and GIM
<b>An 2012(167)</b>	Korea	47	Prospective	ME NBI	100 (MTB) 72 (LBC)	66 (MTB) 96 (LBC)	GIM
<b>Kanzaki 2012(179)</b>	Japan	50 with ECG and CAFG	Cross-sectional study	AFI + ME NBI Body lesser curvature, groove type vs foveola type	Grade of AG-IM significantly higher in groove type compared with foveola type (accuracy figures not supplied)		IM and AG
<b>Savarino 2013(180)</b>	Italy	100	Prospective	NBI ME	80	96	GIM
<b>Fukuta 2013(181)</b>	Japan	163	MC Prospective	WLE IC	WLE: 94.6 (antrum)-86.1 (body) IC: 78.4 (antrum)-86 (body)	WLE: 69.1 (antrum)-65.9 (body) IC: 57.7 (antrum)-82.6 (body)	GIM
<b>Lim 2013(160)</b>	Korea	1333	Prospective	WLE	IM: 24 (antrum)-24.2 (body) AG: 61.5 (antrum)-46.8 (body)	IM: 91.9 (antrum)-88 (body) AG: 57.7 (antrum)-76.4 (body)	GIM and AG
<b>Pittayanon 2013(182)</b>	Thailand	45	Prospective	ME FICE + pCLE	ME FICE: 95.6 ME FICE + pCLE: 96.5	ME FICE: 79.2 ME FICE + pCLE: 90.5	GIM
<b>Xirouchakis 2013(183)</b>	Greece	119	Prospective open	WLE - USP NBI	AG: 86 (WLE-USP)-62 (NBI) GIM: 80 (WLE-USP)-72 (NBI)	AG: 100 (WLE-USP)-97 (NBI) GIM: 100 (WLE-USP)-93 (NBI)	AG and GIM
<b>Nomura 2014(184)</b>	Japan	275	MC prospective	WLE +/- IC	77 (body)-64 (antrum)	79 (body)-54 (antrum)	AG
<b>Panteris 2014(161)</b>	Greece	234	Prospective cross-sectional	WLE	74.6	94	GIM
<b>Kikuste 2014(163)</b>	Latvia	126	Cohort	FICE	60 (diagnosis)-71 (OLGIM III-IV)	87 (diagnosis)-87 (OLGIM III-IV)	GIM
<b>Ang 2015(164)</b>	Asia-Pacific Region	579	MC prospective randomized comparative	WLE NBI	59.1 (WLE)-92.3 (NBI)	98.6 (WLE)-94.3 (NBI)	GIM
<b>Pimentel-Nunes (162)2016</b>	Europe-USA	238	MC prospective	WLE NBI	53 (WLE)-87 (NBI)	98 (WLE)-97 (NBI)	GIM
<b>Sha 2017(185)</b>	China	132	Cohort comparative	(AA-NBI) vs NBI	33.3 (WLE) 66.7 (NBI) 87.9 (AA-NBI)	28.8 (WLE) 68.2 (NBI) 68.2 (AA-NBI)	GIM

AG, atrophic gastritis; GIM, gastric intestinal metaplasia; WLE, white light endoscopy; NBI, narrow band imaging; FICE, flexible spectral imaging colour enhancement; OLGIM, operative link on gastric intestinal metaplasia assessment; MC, multicenter; USP, updated Sydney protocol; LBC, light blue crest; VP, villous pattern; LLC, large long crest; ME, magnification endoscopy; MB, methylene blue; IC, indigocarmine chromoendoscopy; CLE, confocal laser endomicroscopy; pCLE, probe-based confocal laser endomicroscopy; MTB, marginal turbid band; AA-NBI, acetic acid- narrow band imaging; EGC, early gastric cancer; CAFG, chronic atrophic fundic gastritis.

A simplified classification system using NBI without magnification by *Pimentel-Nunes et al* has been shown to be accurate and reliable for the diagnosis of GIM and dysplasia (150). In the validation study a tubulovillous mucosal pattern was associated with GIM (accuracy 84%). Irregular vessels and mucosal pattern were associated with dysplasia (accuracy 95%). The light blue crest (LBC) finding was moderately reliable ( $k=0.49$ ), but very specific (96%) for GIM. In a recent study by Kanemitsu et al.(168), the sensitivity and specificity of LBC for histologically diagnosed IM were 62.5% and 93.8%, respectively. The sensitivity and specificity of WOS were 50.0% and 100.0% (95%CI 85.0% – 100.0%), respectively. The combination of LBC and WOS improved the overall sensitivity up to 87% and 93.8%.

A second prospective multicentre study compared WLE with WLE plus NBI (162). NBI demonstrated a high concordance with histopathological diagnosis, superior to standard WLE. However, it is important to note that this study assessed WLE plus NBI, rather than NBI alone, and although HR WLE had a good overall sensitivity of 85% for all pathology, this decreased to 53% for the detection of GIM. NBI vs WLE increased sensitivity for the diagnosis of intestinal metaplasia significantly (87% vs. 53%;  $P<0.001$ ) and for the diagnosis of dysplasia (92% vs. 74%). This study suggests that WLE alone is therefore not sufficiently accurate for GIM detection. Similar comparative results have been demonstrated in a recent prospective blinded trial (165).

The sensitivity and specificity of WLE for the histological diagnosis of GA were reported to be 61.5% and 57.7%, respectively, in the antrum, and 46.8% and 76.4%, respectively, in the body of the stomach(170).

Compared with WLE, NBI-ME can also effectively diagnose early gastric adenocarcinoma (171).

Thus, in summary, the GDG agreed that WLE alone was not sufficiently accurate to reliably diagnose GA or GIM, and enhanced optical techniques should be used for diagnosis and staging.

A scale for endoscopic staging of GIM using NBI was created and returned an AUC of 0.98 for WLE followed by NBI for diffuse GIM(162). This was externally validated by the same group and for a diagnosis of OLGIM III/VI, the AUC was 0.96 (95% confidence interval 0.93-0.98). This endoscopic grading of GIM (EGGIM) was 89% sensitive and 95% specific for a risk stratification of moderate to severe GIM if a cut off score of  $>4$  was used (186). On this basis, it could be argued that endoscopic staging with HR WLE plus NBI is sufficiently accurate for diagnosis and staging. This is an area of active future research.

### **Gastric dysplasia and early gastric cancer**

Detection of gastric dysplasia and early gastric cancer is notoriously difficult due to the often only subtle findings and the lack of well-defined endoscopic appearances under white light

inspection. Features commonly described, but not exhaustive, include: differences in colour (i.e., more red or pale); loss of vascularity, slight elevation or depression, nodularity, thickening, and abnormal convergence or flattening of folds(187,188).

Therefore, optimal clearing of mucous and secretions is essential to allow for continuous and meticulous search of areas with features different from the surrounding mucosa(189,190).

Recourse to chromoendoscopy with indigo carmine solution (0.2%) or virtual chromoendoscopy (NBI, FICE, i-Scan, BLI) is commonly advocated to enhance contrast and visualization of areas of concern or mucosal abnormalities. Areas of dysplasia may present throughout the stomach, with a slight predominance in antrum and along the lesser curvature, and can vary in size from a few millimeters to several centimeters.

Gastric dysplasia can be morphologically classified into: adenomatous (intestinal), which includes adenomatous polyps; foveolar (gastric); and hybrid type(47,191). Compared to the adenomatous type, the foveolar type appears to be more commonly associated with high grade dysplasia(47,192). Endoscopically, these lesions are usually detected as 0-Is, 0-IIa or 0-IIc types according to the Paris classification of superficial neoplastic lesions(189).

Adenomatous dysplasia is more likely to occur in the gastric body and lesser curvature of the stomach, whereas foveolar dysplasia is more typically located in the gastric antrum and incisura angularis. In addition, foveolar type lesions are smaller, often reddish in colour and present as flat or depressed areas more frequently than the adenomatous type(47).

#### **6.2.4 Biopsy strategy for diagnosis and risk stratification of the pre-malignant stomach**

*What biopsy strategy should be adopted for the sampling and reporting of the pre- and early malignant stomach?*

*Should all those undergoing routine endoscopy be biopsied or are there groups to target?*

**We recommend that patients with image-enhanced features of chronic atrophic gastritis should undergo biopsies for confirmation of endoscopic diagnosis; biopsies are directed at mucosal sites within Sydney protocol areas where enhanced imaging reveals gastric intestinal metaplasia. Biopsies are collected in separate containers and labelled as either ‘directed’ or ‘random’ to corroborate endoscopic staging assessment** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 93%)

**We suggest that a baseline endoscopy with biopsies should be considered in individuals 50 years and over, with laboratory evidence of pernicious anaemia, defined by vitamin B12 deficiency and either positive gastric parietal cell or intrinsic factor antibodies. As atrophy affects the corpus in pernicious anaemia, biopsies should be taken from the greater and lesser curves** (Evidence level: low quality; Grade of recommendation: weak; Level of agreement: 93%)

Biopsies should be undertaken in patients with endoscopic suspicion of GA, GIM, or early neoplasia.

Current surveillance protocols stipulate random biopsies in specified locations according to the updated Sydney protocol (Fig 5). However, random sampling does not reliably foster correlation of endoscopic and histopathologic findings and carries a risk of sampling error. By contrast, ‘directed’ biopsies of mucosal foci suspicious for GIM in areas of the updated Sydney protocol will drive quality control and ultimately propel endoscopy-led staging and risk stratification. This targeted biopsy strategy links endoscopic GIM detection with the well-established OLGIM histopathologic classification scheme. The aforementioned numeric endoscopic classification system for staging of GIM has been shown to correlate strongly with OLGIM and with the extent of GIM (150), further supporting this change in practice. The GDG however did not agree on whether OLGA or OLGIM should be routinely used, principally because there is currently insufficient expertise or capacity for this to be routinely undertaken. Individual units however may choose to adopt this risk stratification system.

### **6.3 Surveillance**

Should individuals with gastric pre-malignant lesions undergo surveillance?

**We recommend endoscopic surveillance every 3 years should be offered to patients diagnosed with extensive gastric atrophy or gastric intestinal metaplasia defined as that affecting the antrum and body** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)

**We do not recommend surveillance in patients with gastric atrophy or gastric intestinal metaplasia limited just to the gastric antrum, unless there are additional risk factors such as a strong family history of gastric cancer or persistent *H. pylori* infection, then we suggest 3 yearly surveillance.** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 93%)

**We recommend patients with non-visible low-grade dysplasia should undergo an immediate second endoscopy with enhanced imaging and extensive biopsy sampling, followed by a repeat endoscopy within 1 year if no visible neoplasia is detected. If there is persistent, non-visible low-grade dysplasia, endoscopy should be repeated annually thereafter.** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)

**We recommend patients with non-visible high-grade dysplasia should undergo an immediate second endoscopy with enhanced imaging and extensive biopsy sampling. We recommend on-going surveillance at 6-monthly intervals for persistent, non-visible high-grade dysplasia. High-grade dysplasia should be discussed at the regional upper GI cancer MDT and referred to a clinician with the appropriate expertise.** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)

#### **6.3.1 Surveillance of chronic atrophic gastritis**

As the neoplastic cascade follows a multistep process from *H. pylori*-associated gastritis through GA and GIM to dysplasia (193), it follows that surveillance of a high-risk population may lead to the detection of early gastric cancer. Furthermore, the evolution of endoscopic



techniques such as ESD with 5 year disease free survival rates of 99% (194), further supports the detection of early gastric cancer through surveillance.

There are several factors which influence the risk of progression to cancer including the extent of atrophy and GIM and a family history of gastric cancer. A strong family history is defined as those with a first degree relative or two or more second degree family members with histologically proven gastric adenocarcinoma. Those at the highest risk with GIM in the antrum and corpus have a 9.8% cumulative 5 year incidence of cancer (26).

#### *Outcomes of endoscopic surveillance of pre-malignant conditions*

There are no randomised controlled studies on the utility of GIM surveillance. There are however observational data. A small UK study assessed the effect of endoscopic surveillance of patients with GIM (specifically type III, incomplete GIM) every 6 to 12 months over a 12 year period. Of the 26 patients surveyed, 11 developed gastric adenocarcinoma which were limited to the mucosa or submucosa at the time of detection. Although 4 patients were lost to follow up, when compared to the unit as a whole, the proportion of early cancers was much greater in surveillance patients (195).

In a second study 166 patients with GIM, dysplasia, GA, ulcers, or polyps were surveyed over 10 years and compared to 1753 open access endoscopy patients. Compared to the open access group, there were more stage I/II cancers (76% vs 23%) and an improved 5 year survival (50% vs 10%) in the surveillance group. 93 of the surveillance patients had GIM of whom 10 developed gastric adenocarcinoma. In patients with GA and GIM the risk of malignancy was 11% (196). Both the aforementioned studies however were conducted before the advent of high resolution and image enhanced endoscopy, which makes it difficult to extrapolate to current practice.

A northern European study in low incidence gastric cancer areas, surveyed 279 patients with GA, GIM or dysplasia over a mean period of 57 months. 1.4% (4 patients) were diagnosed with high-grade dysplasia or gastric cancer, of which 2 were successfully treated by ESD and 2 by gastrectomy. All 4 patients who progressed had extensive GIM as defined by the OLGIM stage. None of those with limited AG or GIM progressed. The overall risk of neoplastic progression was 0.3% per year (197).

There are a number of studies evaluating surveillance in pernicious anaemia and body-predominant atrophic gastritis, however only one study has demonstrated the development of GC in 2/56 patients at the time of a surveillance endoscopy, three years after the initial endoscopy.

The MAPS (Management of precancerous conditions and lesions in the stomach) guidelines published in 2012 recommend that patients with extensive GA and/or extensive GIM should be offered endoscopic surveillance every 3 years (10). MAPS also recommends that patients with mild to moderate atrophy or GIM limited to the antrum do not need follow-up.

#### *Cost effectiveness of endoscopic surveillance of pre-malignant conditions*

The early studies examining the cost effectiveness of CAG surveillance have shown conflicting results, which is partly due to the widely ranging variation in prevalence and progression to

cancer. Modelling undertaken by Yeh et al in 2010 in a US population found surveillance to be cost effective for men over 50 years with dysplasia treated by EMR with annual surveillance (Cost per QALY was US\$39,800), although for 10 yearly surveillance in those with any GIM (US\$544,500) (198). A more recent cost-utility economic analysis in a European population between 50 and 75 years of age aimed to assess the cost effectiveness of endoscopic screening of the pre-malignant stomach using Markov modelling (199). The primary outcome was the incremental cost-effectiveness ratio (ICER) of a 3-yearly endoscopic surveillance versus no surveillance. Endoscopic surveillance every 3 years provided an ICER of € 18,336, well below the adopted threshold of € 36,575 corresponding to the proposed guideline limit of \$ 50,000. Moreover, robustness analysis showed that in 78% of examined scenarios the model was cost-effective. 3 yearly surveillance was found to be more cost effective than 5-10 yearly strategies. Two further studies from low to intermediate risk populations in Singapore utilising Markov modelling and cost-utility analysis, found 1 and 2 yearly surveillance were cost effective, although 3 yearly intervals were not analysed (200,201). In conclusion, recent cost effectiveness models support surveillance in CAG in low to intermediate risk populations between 1 and 3 yearly. These models did not investigate those with extensive CAG where the risk of progression is greater and thus the cost effectiveness is likely to be superior.

As the cancer risk of focal intestinal metaplasia of the cardia is poorly defined and appears much lower than short segment Barretts oesophagus we do not recommend surveillance in this group(43).

### **Summary**

Although there is a lack of randomised data on the survival benefits of surveillance for GIM, there is a moderate evidence base demonstrating progression of pre-malignant conditions, particularly extensive GIM to gastric adenocarcinoma and evolving data from surveillance studies. The cost effectiveness data is also compelling. We do accept however, as with surveillance of Barretts oesophagus, surveillance of GA and GIM will remain controversial. We recommend a surveillance interval of 3 years for those patients with extensive GA or GIM defined as that affecting the antrum and body. However, surveillance may not be appropriate for all patients with extensive atrophy and GIM, particularly the very elderly and those with multiple comorbidities where the benefit of surveillance may be offset by the risks of diagnostic endoscopy. For those with GA or GIM limited to the antrum, but with additional risk factors such as a family history of gastric adenocarcinoma and persistent *H. pylori* infection, we also recommend a surveillance interval of 3 years. Persistent *H.pylori* infection is defined as that refractory to treatment. We also suggest where possible, as with Barrett's oesophagus surveillance, endoscopy is undertaken on a dedicated screening list. The remit of these guidelines do not cover the management of Hereditary Diffuse Gastric Cancer (63).

### **6.3.2 Surveillance of dysplasia**

Although the risk of progression of dysplasia to gastric adenocarcinoma varies between studies, it is clear that HGD confers a greater risk of progression than LGD. 30 % and 85% of patients with HGD progress to cancer with follow up periods of up to 5 years with an estimated annual incidence of 6% (25,44). The overall risk of malignancy for LGD (combining mild and moderate dysplasia, as described in earlier classification systems) varies from 0% to 33% over follow up periods of up to 66 months (202–208). Two of the more recent observational studies have shown progression rates of between 3% and 9% (204,205).

Dysplasia in random biopsies also appears to increase the risk of cancer possibly by as much as 6% per annum(15,25). It is important to note that in those patients found to have incidental HGD or cancer by random biopsies on the index endoscopy, 80% will have a detectable lesion by virtual chromo-endoscopy (209). A finding of gastric dysplasia also carries a high risk of synchronous gastric adenocarcinoma, with rates as high as 30% in some studies (210).

The histopathological biopsy diagnosis may not be representative of the final histopathological grade on excision. This has been described in a meta-analysis of 16 studies including over 3,000 patients. Of patients initially diagnosed with LGD on biopsy, 25% were subsequently diagnosed with more advanced lesions after endoscopic resection (211). Of these 16.7% were HGD and 6.9% were invasive lesions. A Korean series demonstrated a similar upgrade of diagnosis from LGD in 18.7% of cases (212). Thus, the rate of under diagnosis is not insignificant. These data however are discordant with the lower documented progression rates in larger series of up to 9%. The authors found that lesion size larger than 2 cm, surface depression, absence of whitish discoloration, the presence of spontaneous bleeding, and nodularity on endoscopic examination were the major risk factors associated with a higher histopathological grade on excision (211,212). In those patients who undergo surveillance, repeat or multiple biopsies appear to not substantially improve the accuracy of the initial diagnosis (213,214).

Indefinite for dysplasia may also be under or over staged with up to 25% of cases upstaged to dysplasia or cancer(215,216). We therefore recommend patients with indefinite for dysplasia have a review by an expert pathologist and a repeat procedure with image enhancement.

Based on the current body of evidence, there are clear grounds to support the endoscopic resection of visible LGD and HGD, providing the risk of endoscopic resection is justifiable in regards to the health and preference of the patient. We suggest surveillance for HGD and LGD only if resection is not possible or appropriate, or if the dysplasia is not visible, or is the preference of the patient. For patients with LGD undergoing surveillance we recommend surveillance intervals of 1 year with high quality systematic endoscopy. If biopsies are negative for dysplasia after 3 consecutive endoscopies, then consider 3 yearly surveillance. For those with HGD undergoing surveillance, we recommend a repeat high-quality endoscopy, repeated 6 monthly thereafter. All visible dysplasia should be resected where appropriate. There are no cost-effectiveness studies on surveillance of either HGD or LGD and it is unclear for how long surveillance should be continued. For those patients found to have non-visible dysplasia on random biopsies we suggest an immediate systematic endoscopy with enhanced imaging, if necessary in an expert centre.

### **6.3.3 Surveillance after EMR & ESD for dysplasia and early gastric cancer**

The risk of neoplastic synchronous or metachronous lesions as well as recurrence after gastric ESD or EMR is high and varies between 10% and 20% (217–220). Therefore endoscopic surveillance is necessary. This will allow further diagnosis of early neoplastic lesions which can then be removed endoscopically. There is little available data on the follow up interval, however most recurrences occur within the first year after resection (217,221–224). We suggest therefore that a follow up endoscopy is undertaken 6 months after ESD or EMR of neoplasia and if no lesions identified, annually thereafter. This is in line with the Japanese and ESGE guidelines (225–227).

## **6.4 Treatment: Endoscopic therapy**

*What lesions are amenable for endoscopic removal?*

*How should these lesions be removed?*

*Are there criteria on histopathological assessment that determine prognosis and follow up?*

**We recommend that all gastric dysplasia and early gastric adenocarcinoma should be resected in an en-bloc fashion (EMR technique can achieve en-bloc excision for lesions  $\leq 10$ mm in size but only ESD technique can ensure en-bloc excision for lesions  $> 10$ mm in size) (Evidence level: high quality; Grade of recommendation: strong; Level of agreement: 100%)**

**We recommend that complete (R0) endoscopic resection of gastric dysplasia and early gastric adenocarcinoma with the following features should be considered as curative:**

- 1) Low-grade dysplasia**
- 2) High-grade dysplasia**
- 3) Well or moderately differentiated intramucosal adenocarcinoma, irrespective of size and without ulceration**
- 4) Well or moderately differentiated intramucosal adenocarcinoma,  $< 3.0$  cm in size if ulcerated**
- 5) Well or moderately differentiated submucosal adenocarcinoma,  $< 3.0$  cm in size, with superficial submucosal invasion (Sm1;  $< 500$  micron submucosal invasion as measured in a straight line from the deepest fibre of the muscularis mucosae)**
- 6) Poorly differentiated intramucosal adenocarcinoma,  $\leq 2.0$  cm in size**

(Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 93%)

**The histopathological features of early gastric adenocarcinoma associated with a higher risk of lymph node metastasis after endoscopic resection include:**

- 1) Poorly differentiated submucosal, cancer irrespective of invasion depth below muscularis mucosae**
- 2) Signet ring cancer**
- 3) Lympho-vascular invasion**
- 4) Depth of submucosal invasion  $\geq 500$  microns as measured in a straight line from the deepest fibre of the muscularis mucosae**

(Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 93%)

We suggest that where possible, all cases considered for resection should be discussed in an MDT with the appropriate expertise including pathologists and therapeutic endoscopists. When there is no local expertise, patients should be referred to an expert centre. Before any therapeutic procedure is undertaken, the risks and benefits of endoscopic resection and surgery should be discussed with the patient to aid their decision making.

These recommendations apply to the intestinal type of gastric cancer as defined by the Lauren Classification(228,229). Diffuse type adenocarcinoma carries a worse prognosis than intestinal type that appears independent of the T and N stage(229).

The risk of lymph node metastasis (LNM) underpins endoluminal therapy for early gastric adenocarcinoma. This risk has to be weighed against the significant risk of morbidity and

mortality following surgical resection. Endoscopic resection has become the organ-preserving treatment of choice for superficial gastric neoplastic lesions, because of the low risk of LNM that these lesions portend. In a large series from the Far East *Gotoda et al* reviewed the prevalence of LNM in 5265 gastrectomy specimens. On multivariate analysis they found that none of the 979 non-ulcerated lesions had LNM. Additionally, they found that none of the 145 well or moderately differentiated adenocarcinomas measuring less than 30mm, those with submucosal invasion of less than 500 microns (Sm1), and those without lympho-vascular invasion revealed LNM (230). This supported the initial Japanese guidelines on the indication criteria for endoscopic resection of early gastric adenocarcinoma, which included: intestinal type adenocarcinoma, endoscopically diagnosed intramucosal cancer, lesion size of  $\leq 20$ mm and non-ulcerated lesions (226). In a second large series *Hirasawa et al* reviewed 3843 patients who underwent gastrectomy with lymph node dissection for poorly differentiated adenocarcinoma. On multivariate analysis they found that lesion size of  $> 20$ mm, lympho-vascular invasion, and submucosal involvement were independent risk factors for LNM (231).

Overall the two large series on surgically resected early gastric cancer demonstrate that the risk of LNM of superficial lesions is small (less than 1%) if the following criteria are met:

- 1) Well or moderately differentiated intramucosal adenocarcinoma, irrespective of size and without ulceration
- 2) Well or moderately differentiated intramucosal adenocarcinoma,  $\leq 3.0$  cm in size if ulcerated
- 3) Well or moderately differentiated submucosal adenocarcinoma,  $< 3.0$  cm in size, with superficial submucosal invasion (Sm1;  $< 500$  micron submucosal invasion as measured in a straight line from the deepest fibre of the muscularis mucosae)
- 4) Poorly differentiated intramucosal adenocarcinoma,  $< 2.0$  cm in size

This led to the adoption of the expanded indications for ESD of early gastric cancer. The expanded criteria however should not be taken as absolute, particularly where the balance between risk and benefit of surgery is less clear. The original definition of early gastric cancer was defined in 1971 by The Japanese Society of Gastroenterology and Endoscopy as a carcinoma limited to the mucosa and/or submucosa regardless of the lymph node status. This has recently fuelled much controversy as the survival of early gastric cancer is closely associated with the risk of lymph node metastasis. We have therefore adopted the definition of adenocarcinoma limited to the mucosa and superficial submucosa (Sm1;  $< 500$  micron), as that amenable to endoscopic resection.

Two recent series, one from the Far East and one from the West, assessed the outcomes of the extended indications. The series by *Hasuike et al* included 470 lesions, of which 466 (99.1%) were resected en bloc and the curative resection rate 67.4% (232). A similar Western series reported that en bloc resection was achieved in 81/91 lesions (89.0%) and curative resection was achieved in 67/91 lesions (73.6%) (233). The risk of perforation in both series was reported to be up to 2.6%. However, the risk of delayed bleeding was lower in the Western series (2.2% compared to 6.2%). The higher curative resection and lower delayed bleeding rate in the Western series is encouraging, although the number of treated lesions was smaller.

Patient selection is key in achieving favourable outcomes with ESD for early gastric cancer. Patients who do not meet the expanded criteria for a curative outcome following gastric ESD are referred for radical surgery. In a multicentre retrospective study *Hatta et al* developed a

risk-scoring system using multivariate logistic regression analysis of 1101 patients who had undergone radical surgery after failing to meet the criteria for curative endoscopic resection of early gastric cancer (234). Following this, they validated the scoring system in a further 905 patients. They demonstrated that the scoring system known as ‘eCura system’ (Table 6) predicted cancer-specific survival in this cohort of patients. This scoring system is promising but will require further validation in other centres.

Risk factors	Points
<b>Lymphatic invasion</b>	3
<b>Lesion size &gt;30mm</b>	1
<b>Positive vertical margin</b>	1
<b>Venous invasion</b>	1
<b>Submucosal invasion <math>\geq 500 \mu m</math></b>	1

Table 1: Weighted scores for risk factors

Lymph Node Metastasis (LNM) Risk Groups	Points	Risk of LNM (%)	Cancer specific 5-year survival (%)
<b>Low</b>	0-1	2.5	99.6
<b>Intermediate</b>	2-4	6.7	96.0
<b>High</b>	5-7	22.7	90.1

Table 6: eCura system

EMR (cap-assisted) was the initial technique used to resect superficial gastric neoplasia. However, this technique is unable to effectively resect lesions larger than 10mm en bloc. In a recent meta-analysis comparing the efficacy of gastric ESD and EMR, the en bloc and R0 resection rates of EMR were found to be 51.7% and 42.4% (235). This in turn is associated with local recurrence rates as high as 30% (194,217,221,236–239). However, in a subgroup analysis of lesions smaller than 10-15mm, it was noted that there was no difference in survival regardless of the endoscopic resection technique.

ESD was a technique developed to overcome the shortcomings of gastric EMR enabling the en bloc resection of lesions larger than 10mm. In a large series from the Far East of 1033 early gastric cancer lesions, *Oda et al* reported an en bloc resection and R0 resection rate of 98% and 93%, respectively (240). Three meta-analyses comparing the outcomes of EMR and ESD showed that ESD achieved higher en bloc resection rates (92% vs. 52%; odds ratio [OR] 9.69, 95%CI 7.74–12.13), histopathologically complete resection rates (82% vs. 42%; OR 5.66, 95%CI 2.92–10.96) as well as lower recurrence rates (1% vs. 6%; OR 0.10, 95%CI 0.06–0.18) (235,241,242).

The current Japanese Gastroenterological Endoscopy Society and European Society of Gastrointestinal Endoscopy guidelines recommend that ESD is the treatment of choice for most superficial gastric neoplastic lesions (225,243). However, ESD is a technique that is in its infant stages in the West and the complication rates during early adoption can be high. In one European series of 75 patients who underwent gastric ESD en bloc resection was achieved in 85.3% and R0 resection was achieved in 84.0%. However, the complication rate which included delayed bleeding and perforation was as high as 24% (244). Finally, it should be noted that signet ring cancer is not currently recommended for endoscopic resection. However, there

will soon be published prospective data on the treatment of these lesions with ESD if they are less than 20mm which may alter this management strategy.

In summary we recommend where appropriate endoscopic resection as first line therapy for all early gastric neoplasia in line with the Japanese extended indications, favouring ESD over EMR for larger lesions due to the superior R0 resection rate. Surgery should only be undertaken when endoscopic resection is not considered curative or is the preferred patient option.

## **6.5 Treatment: Pharmacological**

*Is there a role for other pharmacological therapies e.g. COX inhibitors and anti-oxidants?*

**We do not recommend the use of NSAIDs or cyclooxygenase (COX) 2 inhibitors to reduce the risk of progression of pre-malignant lesions of the stomach.** (Evidence level: Moderate; Grade of recommendation: Strong; Level of agreement 100%)

**We do not recommend the use of antioxidants as a means to reduce the prevalence of pre-malignant gastric lesions.** (Evidence level: Moderate; Grade of recommendation: Strong; Level of agreement 100%)

### **6.5.1 NSAIDs, aspirin & COX-2 inhibitors**

There are numerous examples of chronic inflammatory conditions that predispose to cancer development. Meta-analyses and retrospective studies have demonstrated that there is a lower incidence of gastric cancer associated with regular, long-term use of NSAIDs including aspirin (245–247). These are thought to reduce carcinogenesis by inhibiting cancer-associated prostaglandins, cytokines, and angiogenic factors. However, their use has been limited by their other gastrointestinal side-effects and there is little in the way of good quality, prospective trials to determine whether they can prevent the progression of pre-malignant gastric lesions.

As such, attention has turned to cyclooxygenase-2 (COX-2) inhibitors with trials particularly focusing on the use of rofecoxib, etodolac, and celecoxib. However, there is limited evidence to support their use because of low quality studies, performed in heterogeneous populations in high gastric cancer incidence countries. There is one placebo-controlled randomised control trial. This trial explored the use of rofecoxib in reversing GIM in those cleared of *H. pylori*. It demonstrated that there was no evidence that rofecoxib causes a regression in GIM over a two-year period (248). Amongst the low-quality trials a study using etodolac on patients who underwent endoscopic early cancer resection found a higher rate of metachronous cancer lesions in those treated with the COX-2 inhibitor (249). Only celecoxib has been suggested to provoke regression of gastric pre-malignant lesions, however, in general these trials are limited to small patient numbers over short periods of time (250–252). A large Swedish population-based case-control study comparing 567 incident cases of gastric cancer and 1165 controls found that aspirin users had a moderately reduced risk of cardia and non-cardia gastric cancer (OR 0.7; 95% CI = 0.6-1.0), although NSAID use had no protective effect in this study (253). A recent literature review of 24 studies suggested that both aspirin and NSAIDs reduce the risk of gastric cancer with a RR of 0.7 (95% CI=0.62-0.80) and 0.86 (95% CI=0.80-0.94), respectively (254). The dose-response analysis indicated that the risk decreased by 11% and 5% for 2 years after a dose increment for both.

Further work is undoubtedly required to address the potential of celecoxib, aspirin, and NSAIDs in the chemoprevention of pre-malignant gastric lesions, in particular in well-designed, randomised, long-term follow-up trials in populations who have a low incidence of gastric cancer. Any benefit must be weighed against the known gastrointestinal side effects of aspirin and NSAIDs.

### **6.5.2 Antioxidants**

There are a limited number of trials exploring the use of anti-oxidants for chemoprevention of gastric premalignant lesions. Three studies have been performed, all in populations with a high incidence of gastric cancer and with generally disappointing results. *Correa et al* demonstrated some benefit with regards to histopathological outcome at 6-years following ascorbic acid and beta-carotene use, but this improvement was lost after 12-years (255) [9]. The other two studies did not demonstrate any benefit of using antioxidants in preventing the progression or causing regression of pre-malignant gastric lesions (256,257).

## **6.6 Endoscopic screening for gastric adenocarcinoma**

Is there evidence to support the introduction of a population screening programme for glandular gastric cancer ?

**We suggest endoscopic screening should be considered in individuals aged 50 or older with multiple risk factors for gastric adenocarcinoma (males, smokers, pernicious anaemia), in particular in those with a first-degree relative with gastric cancer.**

(Evidence level: low quality; Grade of recommendation: weak; Level of agreement: 100%)

**We do not recommend endoscopic screening for gastric adenocarcinoma in the UK population** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)

The evidence addressing the effectiveness of endoscopic screening for prevention of gastric cancer has been garnered from studies conducted in high risk populations (defined as an age-standardised rate (ASR) >20 per 100,000) in Japan and Korea (29.9 and 41.3 respectively) (258). These include 5 cohort studies and 3 case-control studies. Although there are no randomised control trials, the results of the available studies suggest a reduction in mortality from gastric cancer in screened populations. In the more recent regional Japanese cohort studies, there was a reduction in gastric cancer mortality (calculated as the standardised mortality ratio or adjusted relative risk) of 57% and 67% after a 5 and 6 year follow up (259–261) The earlier cohort studies from Japan and China were less convincing but were limited by a broad age distribution and poorly matched cohorts (262,263). The results of the case-control studies were equally variable with a reduction in gastric cancer mortality of between 20% and 80% in high-risk populations in Japan and South Korea (264,265). Based on these results, the authors recommended endoscopic screening in regions of high gastric cancer incidence.

The test characteristics of endoscopic screening have been described in four studies. *Hosokawa* found the sensitivity of endoscopy to be 78% after comparing the gastric cancer incidence in those screened from a cancer registry (266). Similar sensitivities of 69% and 89% have been found across other cancer registries in Japan and South Korea (267–269). In the South Korean



study the gastric cancer detection rates was 2.61 per 1,000 screening endoscopies, with a specificity of 96% (267).

There have been two studies in low incidence regions (defined as an ASR <10 per 100,000) such as the United States of America (3.9 per 100,000), assessing the cost effectiveness of endoscopic screening. The cost of a single screening endoscopy at the age of 50 in the general population was \$115,664 per quality-adjusted life year (QALY), suggesting that endoscopic screening was not cost effective (198,270). Cost-effectiveness analyses in higher risk areas have demonstrated incremental cost-effectiveness ratios (ICER) of \$44,098 and \$25,949 per QALY for annual and biannual screening endoscopy, respectively (200). In a study in Taiwan where patients at the age of 50 who had low levels of pepsinogen-I (<30 ng/ml) were offered endoscopy the ICER was \$29,741 per life year gained (271).

A Markov model of screening in an intermediate risk population (age standardised rate of >10 and <20 per 100,000 population) for ages 50 to 75 years found that upper endoscopy combined with screening colonoscopy (every 10 or 5 years) had an ICER of €15,407/QALY and €30,908/QALY, respectively(272). Stand-alone endoscopic screening (every five years) had an ICER of €70,693/QALY and pepsinogen screening an ICER of €143,344/QALY. This work suggests endoscopic gastric cancer screening in conjunction with a scheduled colonoscopy may be cost-effective in countries with intermediate gastric adenocarcinoma risk such as in Eastern Europe or Portugal. These results imply that resources allocated to endoscopic colorectal cancer screening programs could be used to provide gastric cancer screening, both for detection of high-risk individuals with extensive premalignant conditions and early gastric cancer patients.

Although there is insufficient evidence to support screening in low risk populations, a recent study by *Bodger* and colleagues demonstrated wide variations in rates of elective gastroscopy within general practice populations. They showed that oesophago-gastric cancer patients belonging to practices with low rates of gastroscopy were at increased risk of poor outcome oesophago-gastric cancer. However, if the low referral practices increased to the mid referral range the crude cost per life-year saved for a hypothetical scenario is £140,000, well above a suggested threshold of £25,000. Therefore despite the poorer outcomes, given the high cost implications, primary care physicians should follow a restrictive referral practice (273).

A recent retrospective nationwide Taiwanese propensity-matched cohort study evaluating the impact of non-screening gastroscopy on gastric cancer related mortality found that gastric cancer patients who had undergone gastroscopy in the 5 years before the diagnosis of gastric cancer had a better survival than patients who had never undergone a gastroscopy or whose last gastroscopy was more than 5 years before the diagnosis. The authors found that gastric cancer was detected at an earlier stage in patients who had recently undergone endoscopy. The risk of gastric cancer in this study population is low to moderate. This is the first study showing a significant survival advantage of recent endoscopy in gastric cancer patients in a region of low to moderate gastric cancer incidence (274).

There are factors apart from the pre-malignant stomach that confer a greater risk of gastric adenocarcinoma as described in section 6.1.2. These include family history, particularly those with first degree relatives, pernicious anaemia with an annual incidence of 0.27% in unsubstantiated cases, older age, males and smoking. Ethnicity is also related to an increased risk, but this may be due to a higher prevalence of *H.pylori*. In individuals within low risk

populations who have additional risk factors as described above, screening endoscopy may be of value.

In summary, we suggest only those with multiple risk factors for gastric cancer are considered for screening gastroscopy from the age of 50. If the gastroscopy is normal, then we would not recommend any further screening. Where CAG is diagnosed, this guideline should be followed.

## **6.7 Diagnosis and management of epithelial gastric Polyps**

What are the epithelial gastric polyps and how should they be managed ?

**We recommend that the number of gastric polyps (or estimated number), location of polyps, and size of largest polyp should be clearly documented** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)

**We recommend that gastric polyps other than fundic gland polyps should be biopsied** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)

**We recommend that photo-documentation should be undertaken for all polyps or representative polyps if numerous** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)

**We recommend that if adenomas or hyperplastic polyps are present, the background mucosa should be endoscopically assessed for gastric atrophy, intestinal metaplasia, *H. pylori*, and synchronous neoplasia** (Evidence level: moderate quality; Grade of recommendation: strong; Level of agreement: 100%)

**We recommend that all adenomas should be resected when clinically appropriate and safe to do so** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 100%)

**We recommend that a follow up gastroscopy should be performed at 12 months after complete endoscopic excision of adenomas with on-going surveillance gastroscopy annually thereafter when appropriate** (Evidence level: low quality; Grade of recommendation: strong; Level of agreement: 93%)

**We suggest that hyperplastic polyps >1cm, pedunculated morphology, and those causing symptoms (obstruction, bleeding) should be resected. If present *H. pylori* should be eradicated prior to re-evaluation for endoscopic therapy** (Evidence level: low quality; Grade of recommendation: weak; Level of agreement: 100%)

**We suggest enhanced endoscopic imaging is used to aid characterisation of gastric polyps when there is diagnostic uncertainty following white light examination** (Evidence

level: low quality; Grade of recommendation: weak; Level of agreement: 93%)

The scope of the guidelines is restricted to epithelial polyps and thus neuroendocrine tumours and sub-epithelial polyps have been excluded. Gastric epithelial polyps can be mainly classified in 3 types (107), fundic gland polyps, hyperplastic polyps and adenomatous polyps

### **6.7.1 Fundic gland polyps**

Fundic gland polyps (FGPs) are the most prevalent type of gastric polyps (13-77%) (275) (276). They are typically multiple, small (<1cm), and located in the fundus and corpus. At endoscopy they appear pale, smooth, glassy, and transparent or translucent (Fig 7). Their colour is either lighter or the same colour as the surrounding mucosa. Lacy blood vessels are seen through the translucent surface and the surface shows a pattern of fine grey dots. On enhanced imaging such as NBI, FICE or iScan the surface architecture becomes more prominent. FGPs are usually not associated with an increased risk of cancer, unless in the context of familial adenomatous polyposis syndrome (FAP). However, larger FGPs over 1 cm have been shown to be dysplastic in 1.9% and contain focal cancer also in 1.9%. Fundic gland polyps are associated with long-term PPI use and can spontaneously regress following PPI discontinuation (277). There is no association with background *H. pylori* infection or gastritis.

#### Management of fundic gland polyps

Number, location, morphology, and the size of the largest polyp should be documented. Representative pictures of the polyps should be taken. Diagnosis is easily made by endoscopic appearance as described above, but biopsy confirmation should be sought when in doubt. Large numbers of polyps (>20), young age (<40 yrs), dysplastic appearing polyps (where the typical surface and vascular architecture alters particularly when irregular), and the presence of duodenal adenomas, should lead to exclusion of FAP (107). Fundic gland polyps (FGP) do not require excision unless they have atypical features. Size >1 cm, antral location, ulceration, or an unusual appearance should question the diagnosis of FGP and lead to excision (278). Targeted biopsies should be taken where excision is not undertaken. Patients on long term PPIs should be reevaluated for appropriateness of the PPI, dose of PPI, and alternative treatments (277). There is no role for surveillance gastroscopy for FGPs, except in the setting of FAP (107).

### **6.7.2 Hyperplastic polyps**

Hyperplastic polyps constitute 18-70% of all gastric polyps, are usually single or few in number and are more frequently observed in the antrum or adjacent to ulcers, stomas and gastrectomy sites. They appear as smooth, red buttered with whitish exudates (fibrin) and are dome shaped (Fig 7). They are usually small (0.5–1.5 cm), but can be larger and present as lobulated and pedunculated masses covered with superficial erosions. They are typically associated with *H. pylori* gastritis (25%), GA and GIM. Regression generally occurs after eradication of *H. pylori* (up to 70%)(108).

Gastric hyperplastic polyps can reveal dysplasia (1.9-19%) and malignant transformation (0.6-

2.1%) (279) (280) (281), especially when larger than 1 cm and in the post-gastrectomy stomach, (281–284). A dysplastic hyperplastic polyp is associated with an increased risk of synchronous neoplastic lesions in the surrounding mucosa of approximately 6% (285–291).

Small, white and flat plaques in the fundus have the appearances of hyperplastic polyps with a foveolar pit pattern, but are areas of focal foveolar hyperplasia or more specifically hyperplasia of the foveolar epithelium (292). These have been described as multiple white flat lesion (MWFL) and appear to be more prevalent in those taking PPIs. Histologically, the biopsy specimens from the MWFL included fundic gland parietal cell protrusions and oxyntic gland dilatations. There was no evidence of intestinal metaplasia(293).

#### Management of hyperplastic polyps

Diagnosis of hyperplastic polyps and the absence of dysplasia should be confirmed by histology. The remainder of the stomach should be carefully evaluated for synchronous neoplasia, degree and extent of GA and *H. pylori*. *H. pylori* eradication should be considered in all cases prior to endoscopic resection as many polyps will regress with a repeat endoscopy 3-6 months after eradication (108). Polyps >1cm, pedunculated polyp morphology, or symptomatic polyps (obstruction, bleeding) should be completely resected (282,294). Even when *H. pylori* is present, those polyps >3cm should always be resected as the risk of dysplasia and cancer is high (281,294). Endoscopic surveillance is recommended to monitor the risk of further gastric neoplasia where there is evidence of dysplasia, GA or GIM. The endoscopic surveillance interval should be determined by the stage of CAG.

#### **6.7.3 Adenomatous polyps**

Adenomatous polyps are usually single (82%), small (<2cm), and located in the antrum and incisura angularis. Endoscopically they have a velvety pink lobulated appearance and can be sessile or pedunculated. In Western countries their prevalence varies between 0.5 and 10% (295)(278). They are normally associated with a background of GA and GIM. Coexistence of a synchronous gastric adenocarcinoma has been found in up to 30% of patients with an adenomatous polyp. Moreover, 50% of adenomatous polyps larger than 2cm contain foci of adenocarcinoma (296)(210).

#### Management of Gastric adenomas

Gastric adenomas carry a significant risk of progression to cancer and should be resected where appropriate. Diagnosis of adenoma and degree of dysplasia should be histologically confirmed before treatment is undertaken. A careful evaluation of the stomach should be carried out to identify synchronous neoplasia (30%), GA and GIM. Endoscopic resection is the preferred mode of treatment. An en-bloc excision with ESD is advisable for sessile polyps > 15mm (225) as the possibility of invasive neoplasia in the adenoma is high and ESD reduces the risk of recurrence compared to EMR. A follow up gastroscopy should be performed at 6-12 months after endoscopic resection of adenomas. Patients with adenomas should continue to have surveillance gastroscopy at yearly intervals where appropriate, depending on the number of polyps, their size, and highest grade of dysplasia.

#### **6.7.4 Optical diagnosis of gastric polyps**

Optical enhancement with technology including NBI (Olympus), iScan (Pentax) and FICE (Fujinon) with or without near focus or magnification allows interpretation of the mucosal surface architectural patterns and vasculature. FGPs are characterised by small round pits and a honeycomb microvascular pattern (sensitivity 94.7%, specificity 97.4%), whereas hyperplastic polyps display prolonged or villous pits and a dense vascular pattern (sensitivity 93.6%, specificity 91.6%), respectively (297). The NBI features of gastric adenomas have not been well defined, although a paler colour relative to the background mucosa and a slit-like crypt opening and regular white opaque substance, which corresponds to absorbed subepithelial lipid droplets, are often observed. The brown colour on NBI is due to the subepithelial vessels, which are obscured by lipid droplets accumulated above the subepithelial vessels. A tubular, villous or ridged mucosal structure is generally observed as with colonic adenomas (153,298,299).

Based on the NICE classification validated for colon polyps, a modified NBI classification system has been recently proposed in a retrospective evaluation by two expert reviewers to reliably diagnose low risk gastric polyps (FGPs or hyperplastic polyps < 1cm) with the aim of eliminating the need for biopsy (300).

Relative to the background mucosa, polyps were divided in two groups:

- 1) Lighter or same colour
- 2) Darker

“Lighter or same colour” polyps were further subdivided according to their vascular network in:

- a) Isolated vessels
- b) No vessels
- c) Brown vessels surrounding white structures

Polyps with same or lighter colour and with no vessels or isolated lacy vessels were FGPs in 97-100%. Polyps lighter or similar in colour compared to background mucosa with a homogenous absence of surface pattern were FGPs in 94-100%. The sensitivity and specificity for lacy vessels was 61-66% and 93-96%, respectively, for optical FGP diagnosis. If a lesion had either isolated lacy vessels or homogeneous absence of pattern the NPV for gastric adenoma or cancer was 100%. The NPV for colour same or lighter than background mucosa was 96-97%. Polyps with lighter or same colour as the background mucosa, but larger than 1cm or showing brown vessels surrounding white structures, or those darker in colour require biopsy. Although useful as a research algorithm for assisting decision making, further studies and validation of this classification are required.

All polyps where the mucosal pattern is disorganised, irregular, or absent (amorphous) are suspicious for neoplasia. Likewise, enhanced or irregular vascular patterns are suspicious for neoplasia and targeted biopsies should be taken.

In summary, image enhanced endoscopy (IEE) improves the visualisation of gastric polyps and allows diagnosis of FGPs. Diagnosis of hyperplastic polyps and adenomas with IEE is less

clear, but may aid in the diagnosis of HGD or cancer. We therefore have suggested that IEE is used in all polyps to aid diagnosis and direct biopsies.

It is important to emphasize that the evidence base surrounding the detection, characterisation and management of gastric polyps was generated utilising lower resolution endoscopes and thus there is a need for further studies investigating the accuracy of optical and targeted histological diagnosis with newer endoscopes. Currently, the evidence supports endoscopic resection over biopsy of many non-fundic glandular polyps given the likelihood of upstaging neoplasia (301). This is of particular importance given the risks of bleeding associated with gastric polypectomy.

## **7 Education, audit, and benchmarks and research questions**

### **7.1 Audit and benchmarks**

The prevalence of GIM in patients undergoing endoscopy for dyspepsia is as high as 25% in European studies. The prevalence of GIM is influenced by ethnicity, infection rates with *H. pylori*, age, and family history of gastric cancer. GIM is present in 100% of intestinal type gastric cancer. Detection of GIM is therefore crucial as a first step in order to identify those at risk of gastric adenocarcinoma and may be an obvious benchmark as a quality standard for upper GI endoscopy. The prevalence of gastric atrophy in Western populations is lower than GIM and varies from 0-8% as previously described. We suggest a benchmark of 10 % detection rate for GIM and/or gastric atrophy in those patients undergoing investigation for upper GI symptoms.

### **7.2 Education**

The miss rate for gastric cancer on endoscopy is high and current awareness of the endoscopic features of its precursors, GA, and GIM is low. We would suggest that knowledge in these pathologies is incorporated into the new national gastroenterology curriculum for higher training for gastroenterologists, surgeons, and pathologists.

### **7.3 Service and cost implications of the guidelines**

An extensive service evaluation has not been conducted for this guideline. We have made an estimate of the likely additional work generated by adoption of the guidelines. As discussed, in Western populations (Europe and US) the overall prevalence of CAG in young males and females (below 55 years) was 0-8.3%. In older age groups (above 55 years) the prevalence was reported to be up to 13% (20) and in the EUROGAST study, below 5% (19) and 5.3% in those aged 55-64 years. Of the 1.7 million endoscopies performed per year in the UK approximately 40% are upper GI procedures (302). Thus, in a unit performing a total of 10,000 procedures per year, 4000 will be upper GI endoscopies of which approximately 200 patients will have CAG. Assuming endoscopic diagnostic accuracy of 100% and a CAG prevalence of 5%, this will give rise to 200 additional sets of Sydney biopsies assuming the unit was not previously taking biopsy samples for CAG. This is likely to result in a repeat procedure in a proportion of cases where image enhanced endoscopy was not available during the initial endoscopy. There is no clear data to define the proportion of CAG that extensively affects the stomach and therefore requiring surveillance, but we have estimated this to be 40% of all CAG diagnosed

based on our own experience. We estimate that there will be 130 patients per unit requiring surveillance endoscopy between one and three yearly.

## **7.4 Future Research**

This guideline aims to improve the standardisation of practice in the management of patients at risk of gastric adenocarcinoma. Within this we envisage that improved endoscopic quality, and consequently the detection of CAG and early gastric neoplasia, with targeted surveillance will improve the outcomes of gastric cancer. However, the impact of the guidelines on gastric cancer survival nationally is likely to be small, principally because only a small proportion of patients with gastric cancer will be detected by endoscopy at an early stage. Therefore, studies addressing cost effective, non-invasive, population based screening should be a research priority of the next 5-7 years. The other main priority is a measurable improvement in the quality of gastroscopy.

### Quality standards (QA) & improvement (QI)

- We suggest that a quality improvement bundle for upper GI endoscopy requires derivation and assessment as a priority for research in order to improve diagnostic rates of early gastric neoplasia and its precursors (GA and GIM)
- We suggest that quality indicators are required for systematic gastric surveillance endoscopy and photo-documentation

### Screening & surveillance

- We suggest pilot studies for non-invasive population-based screening strategies for gastric cancer are a research priority
- We suggest that a pilot study is required to assess the cost-effectiveness of endoscopic gastric cancer screening when combined with a screening colonoscopy
- We suggest that further research is required to investigate the optimal surveillance strategy for CAG

### Diagnosis & staging

- We suggest that the accuracy and reproducibility of optical diagnosis and staging of GA and GIM needs to be investigated in a multicentre study
- We suggest research to determine whether the severity and distribution of CAG categorized by OLGA and OLGIM accurately reflect cancer risk during follow-up.
- Cytosponge has been shown to detect cardia intestinal metaplasia (303), but more research is needed to see if this could be a tool to help pick up cardia IM as a triage to endoscopy.
- We suggest that further research is required to investigate the risk of progression of histologically and serologically confirmed pernicious anaemia.
- We suggest that the natural history and risk of progression to cancer of visible and non-visible LGD requires further research.

### Prevalence

- We suggest that further research is required to quantify more accurately the prevalence and extent of GIM in European endoscopy practice

## **8 Conflicts of interest**

There are no declared conflicts of interest from any author

## **9 Planned Review Date**

The guidelines should be considered for review in 5 years from the date of submission for publication estimated to be November 2023.



## Figure captions BSG Guidelines

### Figure 1.

Figure 1 | Normal gastric corpus and antrum mucosal surface pattern with white light, enhanced and magnification endoscopy. The round ‘pit patterns’ of the corpus (Ai) and elongated ‘pit patterns’ of the antrum (Di) can be seen without magnification or enhancement. In the corpus (Ai), the red collecting venules (CV) are evident as well as the round dark red crypt openings (CO). The vascular anatomy becomes more pronounced with NBI (Aii & Dii). The visible anatomical components seen on magnification NBI include the dark brown ‘pit openings’ (PO), the dark brown sub-epithelial capillary network (SECN), and the light brown marginal crypt epithelia (MCE). The corpus mucosa has dark round ‘pit openings’, surrounded by the lighter MCE, followed by the darker circular SECN (Aii & Aiii). In contrast, the dark, oblique ‘pit openings’ in the antrum are grooved so the light coloured ridged or villiform epithelium (MCE) surrounds the dark SECN, termed the ‘groove type pattern’ (Dii & Diii). The corresponding histopathological architecture can be seen in the corpus (B and C) and in the antrum (E and F).

### Figure 2.

Figure 2 | Chronic atrophic gastritis (CAG) and the atrophic border on white light and image enhanced endoscopy. There are four principle endoscopic features of CAG: palor (A, B, C and D), loss of gastric folds (A, B, C and D), prominence of the vessels (A, B, C and D) and the atrophic border (A and B). The paler areas of atrophy are also clear on image enhancement (E and F).

### Figure 3.

Figure 3 | The Integrated and Modified Kimura & Sydney Biopsy System. The modified Kimura staging system divides the extent of atrophy into antrum only (antral), antrum to incisura (antral dominant), antrum to lesser curve (corpus dominant), and antrum, lesser curve and greater curve (pan-atrophy). This system integrates Sydney protocol biopsies which should be taken from the antrum (site 1 and 2), incisura (site 3), lesser curve (site 4) and greater curve (site 5). The anatomical CAG boundaries and biopsy sites can be seen in the splayed (A) and cross-sectional cartoon (B) of the stomach. The biopsy sites defined in the endoscopic retroflexed (C) and forward view (D).

### Figure 4.

Figure 4 | Gastric intestinal metaplasia under white light, image enhanced and magnification endoscopy. Intestinal metaplasia typically appears as small grey-white slightly elevated plaques surrounded by mixed patchy pink and pale areas of mucosa causing an irregular uneven surface (A). These appearances are more evident with image enhancement (B). Corpus GIM can be distinguished from the normal straight/tubular glands of the corpus by a ‘groove type pattern’ similar to that of the antrum or villiform pattern of the intestine and may be appreciated with higher resolution technology on white light endoscopy (C and D). GIM in the antrum is more difficult to characterize as the normal glands are oblique. Additional features of GIM to aid diagnosis in the antrum include the light blue crest (LBC) and the marginal turbid band (MTB) (E). The LBC is a fine, blue-white line on the crest of the epithelial surface seen with NBI enhancement and is a highly accurate sign of the presence of intestinal metaplasia (see text).

### Figure 5.

Figure 5 | Fundic glandular and hyperplastic polyps. A) Fundic glandular polyps seen in the corpus and body. They are either lighter or the same colour as the surrounding mucosa. B) On near view, with image enhancement, lacy blood vessels are seen through the translucent surface and the surface shows a pattern of fine grey dots. C) Hyperplastic polyps are smooth, red buttered with whitish exudates (fibrin) and are dome shaped. The surface vascular pattern is more prominent on image enhancement (D).

Figure 6.

BSG Guidelines for the endoscopic management of chronic atrophic gastritis, gastric dysplasia and gastric epithelial polyps.

## 10 Bibliography

1. Amiri M, Janssen F, Kunst AE. The decline in stomach cancer mortality: exploration of future trends in seven European countries. *Eur J Epidemiol.* 2011 Jan;26(1):23–8.
2. Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia. *World J Gastroenterol.* 2014 Apr 28;20(16):4483–90.
3. Cancer Research UK. Stomach cancer statistics | Cancer Research UK [Internet]. 2016 [cited 2018 Mar 14]. Available from: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/stomach-cancer>
4. Song H, Held M, Sandin S, Rautelin H, Eliasson M, Söderberg S, et al. Increase in the Prevalence of Atrophic Gastritis Among Adults Age 35 to 44 Years Old in Northern Sweden Between 1990 and 2009. *Clin Gastroenterol Hepatol.* 2015 Sep;13(9):1592–600.e1.
5. Anderson WF, Camargo MC, Fraumeni JF, Correa P, Rosenberg PS, Rabkin CS. Age-specific trends in incidence of noncardia gastric cancer in US adults. *JAMA.* 2010 May 5;303(17):1723–8.
6. Maconi G, Manes G, Porro G-B. Role of symptoms in diagnosis and outcome of gastric cancer. *World J Gastroenterol.* 2008 Feb 28;14(8):1149–55.
7. Matsuda T, Saika K. The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan. *Jpn J Clin Oncol.* 2013 Nov;43(11):1157–8.
8. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. *Lancet.* 1975 Jul 12;2(7924):58–60.
9. Correa P. A human model of gastric carcinogenesis. *Cancer Res.* 1988 Jul 1;48(13):3554–60.
10. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). *Endoscopy.* 2012 Jan;44(1):74–94.
11. Tham TCK, Gleeson D, Greenfield SM, Harris A, Cort S. British Society of Gastroenterology policy and processes for the development of guidelines. *Gut.* 2015 Jul;64(7):1184–5.
12. Consortium T. FOR RESEARCH & EVALUATION II.
13. Spence AD, Cardwell CR, McMenamin ÚC, Hicks BM, Johnston BT, Murray LJ, et al. Adenocarcinoma risk in gastric atrophy and intestinal metaplasia: a systematic review. *BMC Gastroenterol.* 2017 Dec 11;17(1):157.
14. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ.* 2008 Apr 26;336(7650):924–6.
15. Song H, Ekhedden IG, Zheng Z, Ericsson J, Nyrén O, Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. *BMJ.* 2015 Jul 27;351:h3867.
16. Miwata T, Quach DT, Hiyama T, Aoki R, Le HM, Tran PLN, et al. Interobserver and intraobserver agreement for gastric mucosa atrophy. *BMC Gastroenterol.* 2015 Aug 4;15:95.
17. Leja M, Funka K, Janciauskas D, Putnins V, Ruskule A, Kikuste I, et al. Interobserver variation in assessment of gastric premalignant lesions: higher agreement for intestinal metaplasia than for atrophy. *Eur J Gastroenterol Hepatol.* 2013 Jun;25(6):694–9.

18. Toyoshima O, Yamaji Y, Yoshida S, Matsumoto S, Yamashita H, Kanazawa T, et al. Endoscopic gastric atrophy is strongly associated with gastric cancer development after *Helicobacter pylori* eradication. *Surg Endosc*. 2017;31(5):2140–8.
19. Webb PM, Hengels KJ, Møller H, Newell DG, Palli D, Elder JB, et al. The epidemiology of low serum pepsinogen A levels and an international association with gastric cancer rates. EUROGAST Study Group. *Gastroenterology*. 1994 Nov;107(5):1335–44.
20. Weck MN, Brenner H. Prevalence of chronic atrophic gastritis in different parts of the world. *Cancer Epidemiol Biomarkers Prev*. 2006 Jun;15(6):1083–94.
21. Choi CE, Sonnenberg A, Turner K, Genta RM. High prevalence of gastric preneoplastic lesions in east asians and hispanics in the USA. *Dig Dis Sci*. 2015 Jul;60(7):2070–6.
22. Namekata T, Miki K, Kimmey M, Fritsche T, Hughes D, Moore D, et al. Chronic atrophic gastritis and *Helicobacter pylori* infection among Japanese Americans in Seattle. *Am J Epidemiol*. 2000 Apr 15;151(8):820–30.
23. Adamu MA, Weck MN, Gao L, Brenner H. Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies. *Eur J Epidemiol*. 2010 Jul;25(7):439–48.
24. Vannella L, Lahner E, Annibale B. Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal. *World J Gastroenterol*. 2012 Mar 28;18(12):1279–85.
25. de Vries AC, van Grieken NCT, Looman CWN, Casparie MK, de Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. *Gastroenterology*. 2008 Apr;134(4):945–52.
26. Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Ushiku T, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after *Helicobacter pylori* eradication. *Gastrointest Endosc*. 2016 Oct;84(4):618–24.
27. Eriksson NK, Kärkkäinen PA, Färkkilä MA, Arkkila PET. Prevalence and distribution of gastric intestinal metaplasia and its subtypes. *Dig Liver Dis*. 2008 May;40(5):355–60.
28. Olmez S, Aslan M, Erten R, Sayar S, Bayram I. The Prevalence of Gastric Intestinal Metaplasia and Distribution of *Helicobacter pylori* Infection, Atrophy, Dysplasia, and Cancer in Its Subtypes. *Gastroenterol Res Pract*. 2015 Nov 9;2015:434039.
29. Eidt S, Stolte M. Prevalence of intestinal metaplasia in *Helicobacter pylori* gastritis. *Scand J Gastroenterol*. 1994 Jul;29(7):607–10.
30. Tulassay Z, Stolte M, Engstrand L, Butruk E, Malfertheiner P, Dítê P, et al. Twelve-month endoscopic and histological analysis following proton-pump inhibitor-based triple therapy in *Helicobacter pylori*-positive patients with gastric ulcers. *Scand J Gastroenterol*. 2010 Sep;45(9):1048–58.
31. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. *Helicobacter pylori* infection and the development of gastric cancer. *N Engl J Med*. 2001 Sep 13;345(11):784–9.
32. Zullo A, Hassan C, Romiti A, Giusto M, Guerriero C, Lorenzetti R, et al. Follow-up of intestinal metaplasia in the stomach: When, how and why. *World J Gastrointest Oncol*. 2012 Mar 15;4(3):30–6.
33. Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. *J Cancer Prev*. 2015 Mar;20(1):25–40.
34. González CA, Sanz-Anquela JM, Companioni O, Bonet C, Berdasco M, López C, et

- al. Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. *J Gastroenterol Hepatol*. 2016 May;31(5):953–8.
35. Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, Guilherme M, Barbosa J, Lomba-Viana H, et al. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. *J Clin Pathol*. 2004 Feb;57(2):177–82.
  36. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. *Am J Gastroenterol*. 2000 Jun;95(6):1431–8.
  37. Vannella L, Lahner E, Osborn J, Bordi C, Miglione M, Delle Fave G, et al. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. *Aliment Pharmacol Ther*. 2010 May;31(9):1042–50.
  38. Lahner E, Bordi C, Cattaruzza MS, Iannoni C, Milione M, Delle Fave G, et al. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of *Helicobacter pylori* infection. *Aliment Pharmacol Ther*. 2005 Sep 1;22(5):471–81.
  39. Rugge M, Fassan M, Pizzi M, Farinati F, Sturniolo GC, Plebani M, et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. *World J Gastroenterol*. 2011 Nov 7;17(41):4596–601.
  40. Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. *Gastrointest Endosc*. 2010 Jun;71(7):1150–8.
  41. Weston AP, Krmpotich P, Makdisi WF, Cherian R, Dixon A, McGregor DH, et al. Short segment Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia. *Am J Gastroenterol*. 1996 May;91(5):981–6.
  42. Johnston MH, Hammond AS, Laskin W, Jones DM. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. *Am J Gastroenterol*. 1996 Aug;91(8):1507–11.
  43. Sharma P, Weston AP, Morales T, Topalovski M, Mayo MS, Sampliner RE. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. *Gut*. 2000 Jan;46(1):9–13.
  44. Sung JK. Diagnosis and management of gastric dysplasia. *Korean J Intern Med*. 2016 Mar;31(2):201–9.
  45. Lauwers GY, Riddell RH. Gastric epithelial dysplasia. *Gut*. 1999 Nov 1;45(5):784–784.
  46. Kim J-W, Jang JY. Optimal management of biopsy-proven low-grade gastric dysplasia. *World J Gastrointest Endosc*. 2015 Apr 16;7(4):396–402.
  47. Baek DH, Kim GH, Park DY, Lee BE, Jeon HK, Lim W, et al. Gastric epithelial dysplasia: characteristics and long-term follow-up results after endoscopic resection according to morphological categorization. *BMC Gastroenterol*. 2015 Feb 12;15(1):17.
  48. Shin CM, Kim N, Yang HJ, Cho S-I, Lee HS, Kim JS, et al. Stomach cancer risk in gastric cancer relatives: interaction between *Helicobacter pylori* infection and family history of gastric cancer for the risk of stomach cancer. *J Clin Gastroenterol*. 2010 Feb;44(2):e34-9.
  49. Lissowska J, Groves FD, Sobin LH, Fraumeni JF, Nasierowska-Guttmejer A, Radziszewski J, et al. Family history and risk of stomach cancer in Warsaw, Poland. *Eur J Cancer Prev*. 1999 Jul;8(3):223–7.

50. Nagase H, Ogino K, Yoshida I, Matsuda H, Yoshida M, Nakamura H, et al. Family History-related Risk of Gastric Cancer in Japan: A Hospital-based Case-Control Study. *Japanese Journal of Cancer Research*. 1996 Oct;87(10):1025–8.
51. Jiang X, Tseng C-C, Bernstein L, Wu AH. Family history of cancer and gastroesophageal disorders and risk of esophageal and gastric adenocarcinomas: a case-control study. *BMC Cancer*. 2014 Feb 4;14:60.
52. Kwak H-W, Choi IJ, Kim CG, Lee JY, Cho S-J, Eom BW, et al. Individual having a parent with early-onset gastric cancer may need screening at younger age. *World J Gastroenterol*. 2015 Apr 21;21(15):4592–8.
53. Reddy KM, Chang JI, Shi JM, Wu BU. Risk of gastric cancer among patients with intestinal metaplasia of the stomach in a US integrated health care system. *Clin Gastroenterol Hepatol*. 2016 Oct;14(10):1420–5.
54. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med*. 2000 Jul 13;343(2):78–85.
55. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. *Lancet Oncol*. 2015 Feb;16(2):e60-70.
56. Rudloff U. Gastric adenocarcinoma and proximal polyposis of the stomach: diagnosis and clinical perspectives. *Clin Exp Gastroenterol*. 2018 Dec 3;11:447–59.
57. Repak R, Kohoutova D, Podhola M, Rejchrt S, Minarik M, Benesova L, et al. The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of the literature. *Gastrointest Endosc*. 2016 Oct;84(4):718–25.
58. Capelle LG, Van Grieken NCT, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. *Gastroenterology*. 2010 Feb;138(2):487–92.
59. Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. *Gastroenterology*. 2010 Dec;139(6):1927–33.
60. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol*. 2015 Feb 3;110(2):223–62; quiz 263.
61. Kluijdt I, Sijmons RH, Hoogerbrugge N, Plukker JT, de Jong D, van Krieken JH, et al. Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. *Fam Cancer*. 2012 Sep;11(3):363–9.
62. van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. *J Med Genet*. 2015 Jun;52(6):361–74.
63. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. *J Med Genet*. 2010 Jul;47(7):436–44.
64. Persson C, Canedo P, Machado JC, El-Omar EM, Forman D. Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. *Am J Epidemiol*. 2011 Feb 1;173(3):259–70.
65. Vannella L, Lahner E, Osborn J, Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. *Aliment Pharmacol Ther*. 2013 Feb;37(4):375–82.
66. Murphy G, Dawsey SM, Engels EA, Ricker W, Parsons R, Etemadi A, et al. Cancer risk after pernicious anemia in the US elderly population. *Clin Gastroenterol Hepatol*. 2015 Dec;13(13):2282–9.e1.

67. Rusak E, Chobot A, Krzywicka A, Wenzlau J. Anti-parietal cell antibodies - diagnostic significance. *Adv Med Sci.* 2016 Sep;61(2):175–9.
68. Minalyan A, Benhammou JN, Artashesyan A, Lewis MS, Pisezna JR. Autoimmune atrophic gastritis: current perspectives. *Clin Exp Gastroenterol.* 2017 Feb 7;10:19–27.
69. Fisher SG, Davis F, Nelson R, Weber L, Goldberg J, Haenszel W. A cohort study of stomach cancer risk in men after gastric surgery for benign disease. *J Natl Cancer Inst.* 1993 Aug 18;85(16):1303–10.
70. Tersmette AC, Goodman SN, Offerhaus GJ, Tersmette KW, Giardiello FM, Vandenbroucke JP, et al. Multivariate analysis of the risk of stomach cancer after ulcer surgery in an Amsterdam cohort of postgastrectomy patients. *Am J Epidemiol.* 1991 Jul 1;134(1):14–21.
71. Viste A, Bjørnstad E, Opheim P, Skarstein A, Thunold J, Hartveit F, et al. Risk of carcinoma following gastric operations for benign disease. A historical cohort study of 3470 patients. *Lancet.* 1986 Aug 30;2(8505):502–5.
72. Schafer LW, Larson DE, Melton LJ, Higgins JA, Ilstrup DM. The risk of gastric carcinoma after surgical treatment for benign ulcer disease. A population-based study in Olmsted County, Minnesota. *N Engl J Med.* 1983 Nov 17;309(20):1210–3.
73. Lagergren J, Lindam A, Mason RM. Gastric stump cancer after distal gastrectomy for benign gastric ulcer in a population-based study. *Int J Cancer.* 2012 Sep 15;131(6):E1048-52.
74. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. *CA Cancer J Clin.* 2006 Apr;56(2):106–30.
75. Ali R, Barnes I, Cairns BJ, Finlayson AE, Bhala N, Mallath M, et al. Incidence of gastrointestinal cancers by ethnic group in England, 2001-2007. *Gut.* 2013 Dec;62(12):1692–703.
76. Lui FH, Tuan B, Swenson SL, Wong RJ. Ethnic disparities in gastric cancer incidence and survival in the USA: an updated analysis of 1992-2009 SEER data. *Dig Dis Sci.* 2014 Dec;59(12):3027–34.
77. Jin H, Pinheiro PS, Xu J, Amei A. Cancer incidence among Asian American populations in the United States, 2009-2011. *Int J Cancer.* 2016 May 1;138(9):2136–45.
78. Dong E, Duan L, Wu BU. Racial and ethnic minorities at increased risk for gastric cancer in a regional US population study. *Clin Gastroenterol Hepatol.* 2017 Apr;15(4):511–7.
79. Pérez-Rodríguez M, Partida-Rodríguez O, Camorlinga-Ponce M, Flores-Luna L, Lazcano E, Gómez A, et al. Polymorphisms in HLA-DQ genes, together with age, sex, and *Helicobacter pylori* infection, as potential biomarkers for the early diagnosis of gastric cancer. *Helicobacter.* 2017 Feb;22(1).
80. Lee T-Y, Wang R-C, Lee Y-C, Lin J-T, Ho HJ, Hsieh M-C, et al. The Incidence of Gastric Adenocarcinoma Among Patients With Gastric Intestinal Metaplasia: A Long-term Cohort Study. *J Clin Gastroenterol.* 2016 Aug;50(7):532–7.
81. Leung WK, Lin SR, Ching JYL, To KF, Ng EKW, Chan FKL, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on *Helicobacter pylori* eradication. *Gut.* 2004 Sep;53(9):1244–9.
82. You WC, Li JY, Blot WJ, Chang YS, Jin ML, Gail MH, et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. *Int J Cancer.* 1999 Nov 26;83(5):615–9.
83. Theuer CP, de Virgilio C, Keese G, French S, Arnell T, Tolmos J, et al. Gastric adenocarcinoma in patients 40 years of age or younger. *Am J Surg.* 1996 Nov;172(5):473–6; discussion 476.

84. Engel LS, Chow W-H, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. *J Natl Cancer Inst.* 2003 Sep 17;95(18):1404–13.
85. Sjødahl K, Lu Y, Nilsen TIL, Ye W, Hveem K, Vatten L, et al. Smoking and alcohol drinking in relation to risk of gastric cancer: a population-based, prospective cohort study. *Int J Cancer.* 2007 Jan 1;120(1):128–32.
86. Nomura AMY, Wilkens LR, Henderson BE, Epplein M, Kolonel LN. The association of cigarette smoking with gastric cancer: the multiethnic cohort study. *Cancer Causes Control.* 2012 Jan;23(1):51–8.
87. Morais S, Rodrigues S, Amorim L, Peleteiro B, Lunet N. Tobacco smoking and intestinal metaplasia: Systematic review and meta-analysis. *Dig Liver Dis.* 2014 Nov;46(11):1031–7.
88. Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. *Cochrane Database Syst Rev.* 2014 Dec 2;(12):CD010623.
89. Ge Z, Ben Q, Qian J, Wang Y, Li Y. Diabetes mellitus and risk of gastric cancer: a systematic review and meta-analysis of observational studies. *Eur J Gastroenterol Hepatol.* 2011 Nov;23(12):1127–35.
90. Tramacere I, Negri E, Pelucchi C, Bagnardi V, Rota M, Scotti L, et al. A meta-analysis on alcohol drinking and gastric cancer risk. *Ann Oncol.* 2012 Jan;23(1):28–36.
91. Lin X-J, Wang C-P, Liu X-D, Yan K-K, Li S, Bao H-H, et al. Body mass index and risk of gastric cancer: a meta-analysis. *Jpn J Clin Oncol.* 2014 Sep;44(9):783–91.
92. Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. *BMJ Open.* 2017 Oct 30;7(10):e017739.
93. Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for *Helicobacter pylori*: a population-based study. *Gut.* 2018;67(1):28–35.
94. Schneider JL, Kolitsopoulos F, Corley DA. Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors. *Aliment Pharmacol Ther.* 2016 Jan;43(1):73–82.
95. BSG Position Statement - Proton pump inhibitors (PPIs) and the risk of gastric cancer [Internet]. [cited 2019 Jan 27]. Available from: <https://www.bsg.org.uk/resource/bsg-position-statement---proton-pump-inhibitors--ppis--and-the-risk-of-gastric-cancer.html>
96. Cai X, Carlson J, Stoicov C, Li H, Wang TC, Houghton J. *Helicobacter felis* eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. *Gastroenterology.* 2005 Jun;128(7):1937–52.
97. Lee C-W, Rickman B, Rogers AB, Ge Z, Wang TC, Fox JG. *Helicobacter pylori* eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. *Cancer Res.* 2008 May 1;68(9):3540–8.
98. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. *Helicobacter pylori* eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. *BMJ.* 2014 May 20;348:g3174.
99. Ford AC, Forman D, Hunt R, Yuan Y, Moayyedi P. *Helicobacter pylori* eradication for the prevention of gastric neoplasia. *Cochrane Database Syst Rev.* 2015 Jul 22;(7):CD005583.
100. Doorackers E, Lagergren J, Engstrand L, Brusselaers N. Eradication of *Helicobacter*



- pylori and Gastric Cancer: A Systematic Review and Meta-analysis of Cohort Studies. *J Natl Cancer Inst.* 2016 Sep;108(9).
101. Lee Y-C, Chiang T-H, Chou C-K, Tu Y-K, Liao W-C, Wu M-S, et al. Association Between *Helicobacter pylori* Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. *Gastroenterology.* 2016 Feb 2;150(5):1113–1124.e5.
  102. O'Connor A, O'Morain CA, Ford AC. Population screening and treatment of *Helicobacter pylori* infection. *Nat Rev Gastroenterol Hepatol.* 2017 Jan 5;14(4):230–40.
  103. Pan K, Zhang L, Gerhard M, Ma J, Liu W, Ulm K, et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of *Helicobacter pylori* in Linqu County, China: baseline results and factors affecting the eradication. *Gut.* 2016 Jan;65(1):9–18.
  104. Chen H-N, Wang Z, Li X, Zhou Z-G. *Helicobacter pylori* eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. *Gastric Cancer.* 2016 Jan;19(1):166–75.
  105. Rokkas T, Rokka A, Portincasa P. A systematic review and meta-analysis of the role of *Helicobacter pylori* eradication in preventing gastric cancer. *Ann Gastroenterol.* 2017 Apr 7;30(4):414–23.
  106. Choi IJ, Kook M-C, Kim Y-I, Cho S-J, Lee JY, Kim CG, et al. *Helicobacter pylori* Therapy for the Prevention of Metachronous Gastric Cancer. *N Engl J Med.* 2018 Mar 22;378(12):1085–95.
  107. Goddard AF, Badreldin R, Pritchard DM, Walker MM, Warren B, British Society of Gastroenterology. The management of gastric polyps. *Gut.* 2010 Sep;59(9):1270–6.
  108. Ohkusa T, Miwa H, Hojo M, Kumagai J, Tanizawa T, Asaoka D, et al. Endoscopic, histological and serologic findings of gastric hyperplastic polyps after eradication of *Helicobacter pylori*: comparison between responder and non-responder cases. *Digestion.* 2003 Oct 24;68(2–3):57–62.
  109. Ohkusa T, Takashimizu I, Fujiki K, Suzuki S, Shimoi K, Horiuchi T, et al. Disappearance of hyperplastic polyps in the stomach after eradication of *Helicobacter pylori*. A randomized, clinical trial. *Ann Intern Med.* 1998 Nov 1;129(9):712–5.
  110. Ji F, Wang Z-W, Ning J-W, Wang Q-Y, Chen J-Y, Li Y-M. Effect of drug treatment on hyperplastic gastric polyps infected with *Helicobacter pylori*: a randomized, controlled trial. *World J Gastroenterol.* 2006 Mar 21;12(11):1770–3.
  111. Ljubicić N, Banić M, Kujundzić M, Antić Z, Vrkljan M, Kovacević I, et al. The effect of eradicating *Helicobacter pylori* infection on the course of adenomatous and hyperplastic gastric polyps. *Eur J Gastroenterol Hepatol.* 1999 Jul;11(7):727–30.
  112. Huang Y, Yu J, Kang W, Ma Z, Ye X, Tian S, et al. Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. *PLoS One.* 2015 Nov 10;10(11):e0142080.
  113. Yeh JM, Hur C, Ward Z, Schrag D, Goldie SJ. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. *Gut.* 2016 Apr;65(4):563–74.
  114. Kuipers EJ. In through the out door: serology for atrophic gastritis. *Eur J Gastroenterol Hepatol.* 2003 Aug;15(8):877–9.
  115. Lomba-Viana R, Dinis-Ribeiro M, Fonseca F, Vieira AS, Bento MJB, Lomba-Viana H. Serum pepsinogen test for early detection of gastric cancer in a European country. *Eur J Gastroenterol Hepatol.* 2012 Jan;24(1):37–41.
  116. Miki K, Fujishiro M, Kodashima S, Yahagi N. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. *Dig Endosc.* 2009 Apr;21(2):78–81.

117. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. *J Med Screen*. 2004;11(3):141–7.
118. Broutet N, Plebani M, Sakarovitch C, Sipponen P, Mégraud F, Eurohepygast Study Group. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. *Br J Cancer*. 2003 Apr 22;88(8):1239–47.
119. Terasawa T, Nishida H, Kato K, Miyashiro I, Yoshikawa T, Takaku R, et al. Prediction of gastric cancer development by serum pepsinogen test and *Helicobacter pylori* seropositivity in Eastern Asians: a systematic review and meta-analysis. *PLoS One*. 2014 Oct 14;9(10):e109783.
120. Yamaguchi Y, Nagata Y, Hiratsuka R, Kawase Y, Tominaga T, Takeuchi S, et al. Gastric Cancer Screening by Combined Assay for Serum Anti-*Helicobacter pylori* IgG Antibody and Serum Pepsinogen Levels--The ABC Method. *Digestion*. 2016 Jan 14;93(1):13–8.
121. Lansdorp-Vogelaar I, Kuipers EJ. Screening for gastric cancer in Western countries. *Gut*. 2016 Apr;65(4):543–4.
122. Ikeda F, Shikata K, Hata J, Fukuhara M, Hirakawa Y, Ohara T, et al. Combination of *Helicobacter pylori* Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study. *J Epidemiol*. 2016 Dec 5;26(12):629–36.
123. Zagari RM, Rabitti S, Greenwood DC, Eusebi LH, Vestito A, Bazzoli F. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-*Helicobacter pylori* antibodies serum assays for the diagnosis of atrophic gastritis. *Aliment Pharmacol Ther*. 2017 Aug 7;46(7):657–67.
124. McNicholl AG, Forné M, Barrio J, De la Coba C, González B, Rivera R, et al. Accuracy of GastroPanel for the diagnosis of atrophic gastritis. *Eur J Gastroenterol Hepatol*. 2014 Sep;26(9):941–8.
125. Masci E, Pellicano R, Mangiavillano B, Luigiano C, Stelitano L, Morace C, et al. GastroPanel® test for non-invasive diagnosis of atrophic gastritis in patients with dyspepsia. *Minerva Gastroenterol Dietol*. 2014 Mar;60(1):79–83.
126. Compare D, Rocco A, Nardone G. Screening for and surveillance of gastric cancer. *World J Gastroenterol*. 2014 Oct 14;20(38):13681–91.
127. Amal H, Leja M, Funka K, Skapars R, Sivins A, Ancans G, et al. Detection of precancerous gastric lesions and gastric cancer through exhaled breath. *Gut*. 2016 Mar;65(3):400–7.
128. Menon S, Trudgill N. How commonly is upper gastrointestinal cancer missed at endoscopy? A meta-analysis. *Endosc Int Open*. 2014 Jun;2(2):E46–50.
129. Beg S, Ragunath K, Wyman A, Banks M, Trudgill N, Pritchard DM, et al. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). *Gut*. 2017 Aug 18;66(11):1886–99.
130. Bisschops R, Areia M, Coron E, Dobru D, Kaskas B, Kuvaev R, et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. *Endoscopy*. 2016 Sep;48(9):843–64.
131. Teh JL, Tan JR, Lau LJF, Saxena N, Salim A, Tay A, et al. Longer examination time improves detection of gastric cancer during diagnostic upper gastrointestinal endoscopy. *Clin Gastroenterol Hepatol*. 2015 Mar;13(3):480–487.e2.
132. Teh JL, Hartman M, Lau L, Tan J-R, Wong A, Ng J-J, et al. Mo1579 duration of endoscopic examination significantly impacts detection rates of neoplastic lesions

- during diagnostic upper endoscopy. *Gastrointest Endosc.* 2011 Apr;73(4):AB393.
133. Taga S. Gastroscopy technique. A. Observation by panendoscopy. In: Tada M, Maruyama M, Fujino M, editors. *I to Cho Handbook*. Tokyo: Igakushoin; 1992. p. 132–9.
  134. JSGCS, The committee for standardizing screening gastroscopy. *Gastric cancer screening techniques. Handbook*. 1st ed. Tokyo: Igakushoin; 2010.
  135. Yao K. The endoscopic diagnosis of early gastric cancer. *Ann Gastroenterol.* 2013;26(1):11–22.
  136. Zhang Q, Chen Z, Chen C, Liu T, Tang X, Ren Y, et al. Training in early gastric cancer diagnosis improves the detection rate of early gastric cancer: an observational study in China. *Medicine.* 2015 Jan;94(2):e384.
  137. Yao K, Uedo N, Muto M, Ishikawa H. Development of an e-learning system for teaching endoscopists how to diagnose early gastric cancer: basic principles for improving early detection. *Gastric Cancer.* 2017 Mar;20(Suppl 1):28–38.
  138. Yao K, Uedo N, Muto M, Ishikawa H, Cardona HJ, Filho ECC, et al. Development of an E-learning System for the Endoscopic Diagnosis of Early Gastric Cancer: An International Multicenter Randomized Controlled Trial. *EBioMedicine.* 2016 Jul;9:140–7.
  139. Nakanishi H, Doyama H, Ishikawa H, Uedo N, Gotoda T, Kato M, et al. Evaluation of an e-learning system for diagnosis of gastric lesions using magnifying narrow-band imaging: a multicenter randomized controlled study. *Endoscopy.* 2017 Oct;49(10):957–67.
  140. Yagi K, Aruga Y, Nakamura A, Sekine A. Regular arrangement of collecting venules (RAC): a characteristic endoscopic feature of *Helicobacter pylori*-negative normal stomach and its relationship with esophago-gastric adenocarcinoma. *J Gastroenterol.* 2005 May;40(5):443–52.
  141. Yagi K, Honda H, Yang JM, Nakagawa S. Magnifying endoscopy in gastritis of the corpus. *Endoscopy.* 2005 Jul;37(7):660–6.
  142. Yagi K, Nakamura A, Sekine A. Comparison between magnifying endoscopy and histological, culture and urease test findings from the gastric mucosa of the corpus. *Endoscopy.* 2002 May;34(5):376–81.
  143. Cho J-H, Chang YW, Jang JY, Shim J-J, Lee CK, Dong SH, et al. Close observation of gastric mucosal pattern by standard endoscopy can predict *Helicobacter pylori* infection status. *J Gastroenterol Hepatol.* 2013 Feb;28(2):279–84.
  144. Na S, Chung J-W, Park HJ, Kim YJ, Kwon KA, Hahm KB, et al. The Usefulness of the Regular Arrangement of Collecting Venules Pattern for the Determination of *Helicobacter pylori* Infection. *Korean J Gastroenterol.* 2011;58(5):252.
  145. Machado RS, Viriato A, Kawakami E, Patrício FRS. The regular arrangement of collecting venules pattern evaluated by standard endoscope and the absence of antrum nodularity are highly indicative of *Helicobacter pylori* uninfected gastric mucosa. *Dig Liver Dis.* 2008 Jan;40(1):68–72.
  146. Muto M, Yao K, Kaise M, Kato M, Uedo N, Yagi K, et al. Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDA-G). *Dig Endosc.* 2016 May;28(4):379–93.
  147. Bansal A, Uluarac O, Mathur S, Sharma P. Correlation between narrow band imaging and nonneoplastic gastric pathology: a pilot feasibility trial. *Gastrointest Endosc.* 2008 Feb;67(2):210–6.
  148. Uedo N. Advanced Imaging in the Diagnosis of Gastric Intestinal Metaplasia: The Expert's Approach. *Video Journal and Encyclopedia of GI Endoscopy.* 2013 Jun;1(1):112–4.

149. Anagnostopoulos GK, Yao K, Kaye P, Fogden E, Fortun P, Shonde A, et al. High-resolution magnification endoscopy can reliably identify normal gastric mucosa, *Helicobacter pylori*-associated gastritis, and gastric atrophy. *Endoscopy*. 2007 Mar;39(3):202–7.
150. Pimentel-Nunes P, Dinis-Ribeiro M, Soares JB, Marcos-Pinto R, Santos C, Rolanda C, et al. A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions. *Endoscopy*. 2012 Mar;44(3):236–46.
151. Gonen C, Simsek I, Sarioglu S, Akpınar H. Comparison of high resolution magnifying endoscopy and standard videoendoscopy for the diagnosis of *Helicobacter pylori* gastritis in routine clinical practice: a prospective study. *Helicobacter*. 2009 Feb;14(1):12–21.
152. Uedo N, Yao K. Endoluminal diagnosis of early gastric cancer and its precursors: bridging the gap between endoscopy and pathology. *Adv Exp Med Biol*. 2016;908:293–316.
153. Yao K, Iwashita A, Tanabe H, Nishimata N, Nagahama T, Maki S, et al. White opaque substance within superficial elevated gastric neoplasia as visualized by magnification endoscopy with narrow-band imaging: a new optical sign for differentiating between adenoma and carcinoma. *Gastrointest Endosc*. 2008 Sep;68(3):574–80.
154. Nakayama Y, Horiuchi A, Kumagai T, Kubota S, Kobayashi M, Sano K, et al. Discrimination of normal gastric mucosa from *Helicobacter pylori* gastritis using standard endoscopes and a single observation site: studies in children and young adults. *Helicobacter*. 2004 Apr;9(2):95–9.
155. Redéen S, Petersson F, Jönsson KA, Borch K. Relationship of gastroscopic features to histological findings in gastritis and *Helicobacter pylori* infection in a general population sample. *Endoscopy*. 2003 Nov;35(11):946–50.
156. Kimura K, Takemoto T. An Endoscopic Recognition of the Atrophic Border and its Significance in Chronic Gastritis. *Endoscopy*. 1969 Sep;1(03):87–97.
157. Naylor GM, Gotoda T, Dixon M, Shimoda T, Gatta L, Owen R, et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. *Gut*. 2006 Nov;55(11):1545–52.
158. Kono S, Gotoda T, Yoshida S, Oda I, Kondo H, Gatta L, et al. Can endoscopic atrophy predict histological atrophy? Historical study in United Kingdom and Japan. *World J Gastroenterol*. 2015 Dec 14;21(46):13113–23.
159. Nagata. Predictability of Gastric Intestinal Metaplasia by Mottled Patchy Erythema Seen on Endoscopy. *Gastroenterology Res*. 2011;
160. Lim JH, Kim N, Lee HS, Choe G, Jo SY, Chon I, et al. Correlation between Endoscopic and Histological Diagnoses of Gastric Intestinal Metaplasia. *Gut Liver*. 2013 Jan 11;7(1):41–50.
161. Panteris V, Nikolopoulou S, Lountou A, Triantafyllidis JK. Diagnostic capabilities of high-definition white light endoscopy for the diagnosis of gastric intestinal metaplasia and correlation with histologic and clinical data. *Eur J Gastroenterol Hepatol*. 2014 Jun;26(6):594–601.
162. Pimentel-Nunes P, Libânio D, Lage J, Abrantes D, Coimbra M, Esposito G, et al. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions. *Endoscopy*. 2016 Aug;48(8):723–30.
163. Kikuste I, Stirna D, Liepniece-Karele I, Leja M, Dinis-Ribeiro M. The accuracy of flexible spectral imaging colour enhancement for the diagnosis of gastric intestinal

- metaplasia: do we still need histology to select individuals at risk for adenocarcinoma? *Eur J Gastroenterol Hepatol*. 2014 Jul;26(7):704–9.
164. Ang TL, Pittayanon R, Lau JYW, Rerknimitr R, Ho SH, Singh R, et al. A multicenter randomized comparison between high-definition white light endoscopy and narrow band imaging for detection of gastric lesions. *Eur J Gastroenterol Hepatol*. 2015 Dec;27(12):1473–8.
  165. Buxbaum JL, Hormozdi D, Dinis-Ribeiro M, Lane C, Dias-Silva D, Sahakian A, et al. Narrow-band imaging versus white light versus mapping biopsy for gastric intestinal metaplasia: a prospective blinded trial. *Gastrointest Endosc*. 2017 Nov;86(5):857–65.
  166. Uedo N, Ishihara R, Iishi H, Yamamoto S, Yamamoto S, Yamada T, et al. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. *Endoscopy*. 2006 Aug;38(8):819–24.
  167. An JK, Song GA, Kim GH, Park DY, Shin NR, Lee BE, et al. Marginal turbid band and light blue crest, signs observed in magnifying narrow-band imaging endoscopy, are indicative of gastric intestinal metaplasia. *BMC Gastroenterol*. 2012 Nov 27;12:169.
  168. Kanemitsu T, Yao K, Nagahama T, Imamura K, Fujiwara S, Ueki T, et al. Extending magnifying NBI diagnosis of intestinal metaplasia in the stomach: the white opaque substance marker. *Endoscopy*. 2017 Jun;49(6):529–35.
  169. Wang L, Huang W, Du J, Chen Y, Yang J. Diagnostic yield of the light blue crest sign in gastric intestinal metaplasia: a meta-analysis. *PLoS One*. 2014 Mar 21;9(3):e92874.
  170. Eshmuratov A, Nah JC, Kim N, Lee HS, Lee HE, Lee BH, et al. The correlation of endoscopic and histological diagnosis of gastric atrophy. *Dig Dis Sci*. 2010 May;55(5):1364–75.
  171. Zhang Q, Wang F, Chen Z-Y, Wang Z, Zhi F-C, Liu S-D, et al. Comparison of the diagnostic efficacy of white light endoscopy and magnifying endoscopy with narrow band imaging for early gastric cancer: a meta-analysis. *Gastric Cancer*. 2016 Apr;19(2):543–52.
  172. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Lara-Santos L, Guilherme M, Moreira-Dias L, et al. Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. *Gastrointest Endosc*. 2003 Apr;57(4):498–504.
  173. Guo YT, Li YQ, Yu T, Zhang TG, Zhang JN, Liu H, et al. Diagnosis of gastric intestinal metaplasia with confocal laser endomicroscopy in vivo: a prospective study. *Endoscopy*. 2008 Jul;40(7):547–53.
  174. Tahara T, Shibata T, Nakamura M, Yoshioka D, Okubo M, Arisawa T, et al. Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. *Gastrointest Endosc*. 2009 Aug;70(2):246–53.
  175. Capelle LG, Haringsma J, de Vries AC, Steyerberg EW, Biermann K, van Dekken H, et al. Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy. *Dig Dis Sci*. 2010 Dec 1;55(12):3442–8.
  176. Kawamura M, Abe S, Oikawa K, Terai S, Saito M, Shibuya D, et al. Topographic differences in gastric micromucosal patterns observed by magnifying endoscopy with narrow band imaging. *J Gastroenterol Hepatol*. 2011 Mar;26(3):477–83.
  177. Rerknimitr R, Imraporn B, Klaikeaw N, Ridditid W, Jutaghokiat S, Ponauthai Y, et al. Non-sequential narrow band imaging for targeted biopsy and monitoring of gastric intestinal metaplasia. *World J Gastroenterol*. 2011 Mar 14;17(10):1336–42.
  178. Dutta AK, Sajith KG, Pulimood AB, Chacko A. Narrow band imaging versus white light gastroscopy in detecting potentially premalignant gastric lesions: a randomized prospective crossover study. *Indian J Gastroenterol*. 2013 Jan;32(1):37–42.

179. Kanzaki H, Uedo N, Ishihara R, Nagai K, Matsui F, Ohta T, et al. Comprehensive investigation of areae gastricae pattern in gastric corpus using magnifying narrow band imaging endoscopy in patients with chronic atrophic fundic gastritis. *Helicobacter*. 2012 Jun;17(3):224–31.
180. Savarino E, Corbo M, Dulbecco P, Gemignani L, Giambruno E, Mastracci L, et al. Narrow-band imaging with magnifying endoscopy is accurate for detecting gastric intestinal metaplasia. *World J Gastroenterol*. 2013 May 7;19(17):2668–75.
181. Fukuta N, Ida K, Kato T, Uedo N, Ando T, Watanabe H, et al. Endoscopic diagnosis of gastric intestinal metaplasia: a prospective multicenter study. *Dig Endosc*. 2013 Sep;25(5):526–34.
182. Pittayanon R, Rerknimitr R, Wisedopas N, Ridditid W, Kongkam P, Treeprasertsuk S, et al. Flexible spectral imaging color enhancement plus probe-based confocal laser endomicroscopy for gastric intestinal metaplasia detection. *J Gastroenterol Hepatol*. 2013 Jun;28(6):1004–9.
183. Xirouchakis E, Laoudi F, Tsartsali L, Spiliadi C, Georgopoulos SD. Screening for gastric premalignant lesions with narrow band imaging, white light and updated Sydney protocol or both? *Dig Dis Sci*. 2013 Apr;58(4):1084–90.
184. Nomura S, Ida K, Terao S, Adachi K, Kato T, Watanabe H, et al. Endoscopic diagnosis of gastric mucosal atrophy: multicenter prospective study. *Dig Endosc*. 2014 Nov;26(6):709–19.
185. Sha J, Wang P, Zhu B, Zhu M, Li X, Gao F. Acetic acid enhanced narrow band imaging for the diagnosis of gastric intestinal metaplasia. *PLoS One*. 2017 Jan 30;12(1):e0170957.
186. Libânio D, Braga V, Ferraz S, Castro R, Lage J, Pita I, et al. Prospective comparative study of endoscopic submucosal dissection and gastrectomy for early neoplastic lesions including patients' perspectives. *Endoscopy*. 2019 Jan;51(1):30–9.
187. Axon A. Symptoms and diagnosis of gastric cancer at early curable stage. *Best Pract Res Clin Gastroenterol*. 2006;20(4):697–708.
188. Coda S, Lee S-Y, Gotoda T. Endoscopic mucosal resection and endoscopic submucosal dissection as treatments for early gastrointestinal cancers in Western countries. *Gut Liver*. 2007 Jun 30;1(1):12–21.
189. Endoscopic Classification Review Group. Update on the paris classification of superficial neoplastic lesions in the digestive tract. *Endoscopy*. 2005 Jun;37(6):570–8.
190. Veitch AM, Uedo N, Yao K, East JE. Optimizing early upper gastrointestinal cancer detection at endoscopy. *Nat Rev Gastroenterol Hepatol*. 2015 Nov;12(11):660–7.
191. Lauwers GY. Defining the pathologic diagnosis of metaplasia, atrophy, dysplasia, and gastric adenocarcinoma. *J Clin Gastroenterol*. 2003 Jun;36(5 Suppl):S37–43; discussion S61.
192. Park DY, Srivastava A, Kim GH, Mino-Kenudson M, Deshpande V, Zukerberg LR, et al. Adenomatous and foveolar gastric dysplasia: distinct patterns of mucin expression and background intestinal metaplasia. *Am J Surg Pathol*. 2008 Apr;32(4):524–33.
193. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, et al. Gastric precancerous process in a high risk population: cohort follow-up. *Cancer Res*. 1990 Aug 1;50(15):4737–40.
194. Uedo N, Iishi H, Tatsuta M, Ishihara R, Higashino K, Takeuchi Y, et al. Longterm outcomes after endoscopic mucosal resection for early gastric cancer. *Gastric Cancer*. 2006;9(2):88–92.
195. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. *Gut*. 1991 Oct 1;32(10):1110–3.

196. Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JWL. The long term results of endoscopic surveillance of premalignant gastric lesions. *Gut*. 2002 Mar;50(3):378–81.
197. den Hollander WJ, Holster IL, den Hoed CM, Capelle LG, Tang TJ, Anten M-P, et al. Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. *Gut*. 2018 Jun 6;
198. Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ. Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. *Cancer*. 2010 Jun 15;116(12):2941–53.
199. Areia M, Dinis-Ribeiro M, Rocha Gonçalves F. Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions. *Helicobacter*. 2014 Dec;19(6):425–36.
200. Zhou HJ, Dan YY, Naidoo N, Li SC, Yeoh KG. A cost-effectiveness analysis evaluating endoscopic surveillance for gastric cancer for populations with low to intermediate risk. *PLoS One*. 2013 Dec 27;8(12):e83959.
201. Wu JT, Zhou J, Naidoo N, Yang WY, Lin XC, Wang P, et al. Determining the cost-effectiveness of endoscopic surveillance for gastric cancer in patients with precancerous lesions. *Asia Pac J Clin Oncol*. 2016 Dec;12(4):359–68.
202. Di Gregorio C, Morandi P, Fante R, De Gaetani C. Gastric dysplasia. A follow-up study. *Am J Gastroenterol*. 1993 Oct;88(10):1714–9.
203. Fertitta AM, Comin U, Terruzzi V, Minoli G, Zambelli A, Cannatelli G, et al. Clinical significance of gastric dysplasia: a multicenter follow-up study. *Gastrointestinal Endoscopic Pathology Study Group. Endoscopy*. 1993 May;25(4):265–8.
204. Yamada H, Ikegami M, Shimoda T, Takagi N, Maruyama M. Long-term follow-up study of gastric adenoma/dysplasia. *Endoscopy*. 2004 May;36(5):390–6.
205. Rugge M, Cassaro M, Di Mario F, Leo G, Leandro G, Russo VM, et al. The long term outcome of gastric non-invasive neoplasia. *Gut*. 2003 Aug;52(8):1111–6.
206. Park SY, Jeon SW, Jung MK, Cho CM, Tak WY, Kweon YO, et al. Long-term follow-up study of gastric intraepithelial neoplasias: progression from low-grade dysplasia to invasive carcinoma. *Eur J Gastroenterol Hepatol*. 2008 Oct;20(10):966–70.
207. Kokkola A, Haapiainen R, Laxén F, Puolakkainen P, Kivilaakso E, Virtamo J, et al. Risk of gastric carcinoma in patients with mucosal dysplasia associated with atrophic gastritis: a follow up study. *J Clin Pathol*. 1996 Dec;49(12):979–84.
208. Rugge M, Farinati F, Baffa R, Sonogo F, Di Mario F, Leandro G, et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. *Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology*. 1994 Nov;107(5):1288–96.
209. Simone A, Casadei A, De Vergori E, Morgagni P, Saragoni L, Ricci E. Rescue endoscopy to identify site of gastric dysplasia or carcinoma found at random biopsies. *Dig Liver Dis*. 2011 Sep;43(9):721–5.
210. Abraham SC, Park SJ, Lee J-H, Mugartegui L, Wu T-T. Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes. *Mod Pathol*. 2003 Aug;16(8):786–95.
211. Zhao G, Xue M, Hu Y, Lai S, Chen S, Wang L. How Commonly Is the Diagnosis of Gastric Low Grade Dysplasia Upgraded following Endoscopic Resection? A Meta-Analysis. *PLoS One*. 2015 Jul 16;10(7):e0132699.
212. Kim YJ, Park JC, Kim JH, Shin SK, Lee SK, Lee YC, et al. Histologic diagnosis based on forceps biopsy is not adequate for determining endoscopic treatment of gastric adenomatous lesions. *Endoscopy*. 2010 Aug;42(8):620–6.
213. Nam KW, Song KS, Lee HY, Lee BS, Seong JK, Kim SH, et al. Spectrum of final

- pathological diagnosis of gastric adenoma after endoscopic resection. *World J Gastroenterol*. 2011 Dec 21;17(47):5177–83.
214. Jeon HK, Ryu HY, Cho MY, Kim H-S, Kim JW, Park HJ, et al. A randomized trial to determine the diagnostic accuracy of conventional vs. jumbo forceps biopsy of gastric epithelial neoplasias before endoscopic submucosal dissection; open-label study. *Gastric Cancer*. 2014 Oct;17(4):661–8.
  215. Goo JJ, Choi CW, Kang DH, Kim HW, Park SB, Cho M, et al. Risk factors associated with diagnostic discrepancy of gastric indefinite neoplasia: Who need en bloc resection? *Surg Endosc*. 2015 Dec;29(12):3761–7.
  216. Raftopoulos SC, Kumarasinghe P, de Boer B, Iacobelli J, Kontorinis N, Fermoyle S, et al. Gastric intraepithelial neoplasia in a Western population. *Eur J Gastroenterol Hepatol*. 2012 Jan;24(1):48–54.
  217. Pimentel-Nunes P, Mourão F, Veloso N, Afonso LP, Jácome M, Moreira-Dias L, et al. Long-term follow-up after endoscopic resection of gastric superficial neoplastic lesions in Portugal. *Endoscopy*. 2014 Nov;46(11):933–40.
  218. Pyo JH, Lee H, Min B-H, Lee JH, Choi MG, Lee JH, et al. Long-Term Outcome of Endoscopic Resection vs. Surgery for Early Gastric Cancer: A Non-inferiority-Matched Cohort Study. *Am J Gastroenterol*. 2016 Feb;111(2):240–9.
  219. Kosaka T, Endo M, Toya Y, Abiko Y, Kudara N, Inomata M, et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a single-center retrospective study. *Dig Endosc*. 2014 Mar;26(2):183–91.
  220. Kato M, Nishida T, Yamamoto K, Hayashi S, Kitamura S, Yabuta T, et al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. *Gut*. 2013 Oct;62(10):1425–32.
  221. Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Fukuda K, et al. Risk for local recurrence of early gastric cancer treated with piecemeal endoscopic mucosal resection during a 10-year follow-up period. *Surg Endosc*. 2012 Jan;26(1):72–8.
  222. Ahn JY, Jung HY, Choi JY, Kim MY, Lee JH, Choi KS, et al. Natural course of noncurative endoscopic resection of differentiated early gastric cancer. *Endoscopy*. 2012 Dec;44(12):1114–20.
  223. Oda I, Gotoda T, Sasako M, Sano T, Katai H, Fukagawa T, et al. Treatment strategy after non-curative endoscopic resection of early gastric cancer. *Br J Surg*. 2008 Dec;95(12):1495–500.
  224. Yoon H, Kim SG, Choi J, Im JP, Kim JS, Kim WH, et al. Risk factors of residual or recurrent tumor in patients with a tumor-positive resection margin after endoscopic resection of early gastric cancer. *Surg Endosc*. 2013 May;27(5):1561–8.
  225. Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, Repici A, Vieth M, De Ceglie A, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy*. 2015 Sep;47(9):829–54.
  226. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). *Gastric Cancer*. 2011 Jun;14(2):113–23.
  227. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer*. 2017 Jan;20(1):1–19.
  228. Lauren P. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. *Acta Pathol Microbiol Scand*. 1965;64:31–49.
  229. Qiu M, Cai M, Zhang D, Wang Z, Wang D, Li Y, et al. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric



- adenocarcinoma in China. *J Transl Med.* 2013 Mar 6;11:58.
230. Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. *Gastric Cancer.* 2000 Dec;3(4):219–25.
  231. Hirasawa T, Gotoda T, Miyata S, Kato Y, Shimoda T, Taniguchi H, et al. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. *Gastric Cancer.* 2009 Nov 5;12(3):148–52.
  232. Hasuike N, Ono H, Boku N, Mizusawa J, Takizawa K, Fukuda H, et al. A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). *Gastric Cancer.* 2018 Jan;21(1):114–23.
  233. Probst A, Schneider A, Schaller T, Anthuber M, Ebigbo A, Messmann H. Endoscopic submucosal dissection for early gastric cancer: are expanded resection criteria safe for Western patients? *Endoscopy.* 2017 Sep;49(9):855–65.
  234. Hatta W, Gotoda T, Oyama T, Kawata N, Takahashi A, Yoshifuku Y, et al. A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: “eCura system”. *Am J Gastroenterol.* 2017 Jun;112(6):874–81.
  235. Facciorusso A, Antonino M, Di Maso M, Muscatiello N. Endoscopic submucosal dissection vs endoscopic mucosal resection for early gastric cancer: A meta-analysis. *World J Gastrointest Endosc.* 2014 Nov 16;6(11):555–63.
  236. Takekoshi T, Baba Y, Ota H, Kato Y, Yanagisawa A, Takagi K, et al. Endoscopic resection of early gastric carcinoma: results of a retrospective analysis of 308 cases. *Endoscopy.* 1994 May;26(4):352–8.
  237. Hiki Y, Shima H, Mieno H, Sakakibara Y, Kobayashi N, Saigenji K. Modified treatment of early gastric cancer: evaluation of endoscopic treatment of early gastric cancers with respect to treatment indication groups. *World J Surg.* 1995 Aug;19(4):517–22.
  238. Nagano H, Ohyama S, Fukunaga T, Seto Y, Fujisaki J, Yamaguchi T, et al. Indications for gastrectomy after incomplete EMR for early gastric cancer. *Gastric Cancer.* 2005;8(3):149–54.
  239. Tanabe S, Ishido K, Higuchi K, Sasaki T, Katada C, Azuma M, et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a retrospective comparison with conventional endoscopic resection in a single center. *Gastric Cancer.* 2014 Jan;17(1):130–6.
  240. Oda I, Gotoda T, Hamanaka H, Eguchi T, Saito Y, Matsuda T, et al. Endoscopic submucosal dissection for early gastric cancer: technical feasibility, operation time and complications from a large consecutive series. *Dig Endosc.* 2005 Jan;17(1):54–8.
  241. Lian J, Chen S, Zhang Y, Qiu F. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. *Gastrointest Endosc.* 2012 Oct;76(4):763–70.
  242. Park Y-M, Cho E, Kang H-Y, Kim J-M. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. *Surg Endosc.* 2011 Aug;25(8):2666–77.
  243. Ono H, Yao K, Fujishiro M, Oda I, Nimura S, Yahagi N, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. *Dig Endosc.* 2016 Jan;28(1):3–15.
  244. Farhat S, Chaussade S, Ponchon T, Coumaros D, Charachon A, Barrioz T, et al. Endoscopic submucosal dissection in a European setting. A multi-institutional report of a technique in development. *Endoscopy.* 2011 Aug;43(8):664–70.
  245. Wu C-Y, Wu M-S, Kuo KN, Wang C-B, Chen Y-J, Lin J-T. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in

- Helicobacter pylori-infected patients. *J Clin Oncol*. 2010 Jun 20;28(18):2952–7.
246. Tian W, Zhao Y, Liu S, Li X. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. *Eur J Cancer Prev*. 2010 Jul;19(4):288–98.
  247. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC-Y. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. *J Natl Cancer Inst*. 2003 Dec 3;95(23):1784–91.
  248. Leung WK, Ng EKW, Chan FKL, Chan WY, Chan K, Auyeung ACM, et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. *Clin Cancer Res*. 2006 Aug 1;12(15):4766–72.
  249. Yanaoka K, Oka M, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S, et al. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. *Int J Cancer*. 2010 Mar 15;126(6):1467–73.
  250. Hung K-H, Yang H-B, Cheng H-C, Wu J-J, Sheu B-S. Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication. *J Gastroenterol Hepatol*. 2010 Jan;25(1):48–53.
  251. Yang HB, Cheng HC, Sheu BS, Hung KH, Liou MF, Wu JJ. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. *Aliment Pharmacol Ther*. 2007 Feb 15;25(4):455–61.
  252. Zhang L-J, Wang S-Y, Huo X-H, Zhu Z-L, Chu J-K, Ma J-C, et al. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. *World J Gastroenterol*. 2009 Jun 14;15(22):2731–8.
  253. Akre K, Ekström AM, Signorello LB, Hansson LE, Nyrén O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. *Br J Cancer*. 2001 Apr 6;84(7):965–8.
  254. Huang X-Z, Chen Y, Wu J, Zhang X, Wu C-C, Zhang C-Y, et al. Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis. *Oncotarget*. 2017 Jan 17;8(3):4781–95.
  255. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. *J Natl Cancer Inst*. 2000 Dec 6;92(23):1881–8.
  256. You W, Brown LM, Zhang L, Li J, Jin M, Chang Y, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. *J Natl Cancer Inst*. 2006 Jul 19;98(14):974–83.
  257. Plummer M, Vivas J, Lopez G, Bravo JC, Peraza S, Carillo E, et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population. *J Natl Cancer Inst*. 2007 Jan 17;99(2):137–46.
  258. Ferlay J. Cancer incidence and mortality worldwide. Ervik M, editor. Lyon, France: International Agency for Research on Cancer; 2013.
  259. Hamashima C, Ogoshi K, Narisawa R, Kishi T, Kato T, Fujita K, et al. Impact of endoscopic screening on mortality reduction from gastric cancer. *World J Gastroenterol*. 2015 Feb 28;21(8):2460–6.
  260. Hamashima C, Shabana M, Okada K, Okamoto M, Osaki Y. Mortality reduction from gastric cancer by endoscopic and radiographic screening. *Cancer Sci*. 2015 Dec;106(12):1744–9.
  261. Hosokawa O, Shinbo T, Matsuda K, Miyakawa T. Impact of opportunistic endoscopic screening on the decrease of mortality from gastric cancer. *J Gastroint Cancer Screen*. 2011 Jun 15;106:401–7.

262. Riecken B, Pfeiffer R, Ma JL, Jin ML, Li JY, Liu WD, et al. No impact of repeated endoscopic screens on gastric cancer mortality in a prospectively followed Chinese population at high risk. *Prev Med.* 2002 Jan;34(1):22–8.
263. Matsumoto S, Yamasaki K, Tsuji K, Shirahama S. Results of mass endoscopic examination for gastric cancer in Kamigoto Hospital, Nagasaki Prefecture. *World J Gastroenterol.* 2007 Aug 28;13(32):4316–20.
264. Matsumoto S, Yoshida Y. Efficacy of endoscopic screening in an isolated island: a case-control study. *Indian J Gastroenterol.* 2014 Jan;33(1):46–9.
265. Hamashima C, Ogoshi K, Okamoto M, Shabana M, Kishimoto T, Fukao A. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. *PLoS One.* 2013 Nov 13;8(11):e79088.
266. Hosokawa O, Hattori M, Takeda T, Watanabe T, Fujita M. Accuracy of endoscopy in detecting gastric cancer. *J Gastroenterol Mass Surv.* 2004 Jun 15;14:33–39.
267. Choi KS, Jun JK, Park E-C, Park S, Jung KW, Han MA, et al. Performance of different gastric cancer screening methods in Korea: a population-based study. *PLoS One.* 2012 Nov 29;7(11):e50041.
268. Hamashima C, Okamoto M, Shabana M, Osaki Y, Kishimoto T. Sensitivity of endoscopic screening for gastric cancer by the incidence method. *Int J Cancer.* 2013 Aug 1;133(3):653–9.
269. Otsuji M, Kouno Y, Otsuji A, Tokushige J, Shimotatara K, Arimura K. Assessment of small diameter panendoscopy for diagnosis of gastric cancer: comparative study with follow-up survey date. *Stomach Intest.* 1989;24:1291–1297.
270. Gupta N, Bansal A, Wani SB, Gaddam S, Rastogi A, Sharma P. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. *Gastrointest Endosc.* 2011 Sep;74(3):610–624.e2.
271. Lee Y-C, Lin J-T, Wu H-M, Liu T-Y, Yen M-F, Chiu H-M, et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. *Cancer Epidemiol Biomarkers Prev.* 2007 May;16(5):875–85.
272. Areia M, Spaander MC, Kuipers EJ, Dinis-Ribeiro M. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk. *United European Gastroenterol J.* 2017 Jul 18;205064061772290.
273. Shaihi M, Thompson E, Kapoor N, Powell G, Sturges RP, Stern N, et al. Variation in gastroscopy rate in English general practice and outcome for oesophagogastric cancer: retrospective analysis of Hospital Episode Statistics. *Gut.* 2014 Feb;63(2):250–61.
274. Leung WK, Ho HJ, Lin J-T, Wu M-S, Wu C-Y. Prior gastroscopy and mortality in patients with gastric cancer: a matched retrospective cohort study. *Gastrointest Endosc.* 2018 Jan;87(1):119–127.e3.
275. Carmack SW, Genta RM, Graham DY, Lauwers GY. Management of gastric polyps: a pathology-based guide for gastroenterologists. *Nat Rev Gastroenterol Hepatol.* 2009 Jun;6(6):331–41.
276. ASGE Standards of Practice Committee, Evans JA, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. *Gastrointest Endosc.* 2015 Jul;82(1):1–8.
277. Graham JR. Gastric polyposis: onset during long-term therapy with omeprazole. *Med J Aust.* 1992 Aug 17;157(4):287–8.
278. Chandrasekhara V, Ginsberg GG. Endoscopic management of gastrointestinal stromal tumors. *Curr Gastroenterol Rep.* 2011 Dec;13(6):532–9.
279. Islam RS, Patel NC, Lam-Himlin D, Nguyen CC. Gastric polyps: a review of clinical,

- endoscopic, and histopathologic features and management decisions. *Gastroenterol Hepatol (NY)*. 2013 Oct;9(10):640–51.
280. Han JS, Jang JS, Choi SR, Kwon HC, Kim MC, Jeong JS, et al. A study of metachronous cancer after endoscopic resection of early gastric cancer. *Scand J Gastroenterol*. 2011 Sep;46(9):1099–104.
  281. Ahn JY, Son DH, Choi KD, Roh J, Lim H, Choi K-S, et al. Neoplasms arising in large gastric hyperplastic polyps: endoscopic and pathologic features. *Gastrointest Endosc*. 2014 Dec;80(6):1005–13.e2.
  282. Kang HM, Oh TH, Seo JY, Joen TJ, Seo DD, Shin WC, et al. [Clinical factors predicting for neoplastic transformation of gastric hyperplastic polyps]. *Korean J Gastroenterol*. 2011 Oct 25;58(4):184–9.
  283. Daibo M, Itabashi M, Hirota T. Malignant transformation of gastric hyperplastic polyps. *Am J Gastroenterol*. 1987 Oct;82(10):1016–25.
  284. Dirschmid K, Platz-Baudin C, Stolte M. Why is the hyperplastic polyp a marker for the precancerous condition of the gastric mucosa? *Virchows Arch*. 2006 Jan;448(1):80–4.
  285. Ginsberg GG, Al-Kawas FH, Fleischer DE, Reilly HF, Benjamin SB. Gastric polyps: relationship of size and histology to cancer risk. *Am J Gastroenterol*. 1996 Apr;91(4):714–7.
  286. Rattan J, Arber N, Tiomny E, Moshkowitz M, Chapsky Y, Baratz M, et al. Gastric polypoid lesions--an eight-year study. *Hepatogastroenterology*. 1993 Apr;40(2):107–9.
  287. Hizawa K, Fuchigami T, Iida M, Aoyagi K, Iwashita A, Daimaru Y, et al. Possible neoplastic transformation within gastric hyperplastic polyp. Application of endoscopic polypectomy. *Surg Endosc*. 1995 Jun;9(6):714–8.
  288. Zea-Iriarte WL, Sekine I, Itsuno M, Makiyama K, Naito S, Nakayama T, et al. Carcinoma in gastric hyperplastic polyps. A phenotypic study. *Dig Dis Sci*. 1996 Feb;41(2):377–86.
  289. Cristallini EG, Ascani S, Bolis GB. Association between histologic type of polyp and carcinoma in the stomach. *Gastrointest Endosc*. 1992 Aug;38(4):481–4.
  290. Harju E. Gastric polyposis and malignancy. *Br J Surg*. 1986 Jul;73(7):532–3.
  291. Markowski AR, Markowska A, Guzinska-Ustymowicz K. Pathophysiological and clinical aspects of gastric hyperplastic polyps. *World J Gastroenterol*. 2016 Oct 28;22(40):8883–91.
  292. Uedo N, Yamaoka R, Yao K. Multiple white flat lesions in the gastric corpus are not intestinal metaplasia. *Endoscopy*. 2017 Jun;49(6):615–6.
  293. Hasegawa R, Yao K, Ihara S, Miyaoka M, Kanemitsu T, Chuman K, et al. Magnified endoscopic findings of multiple white flat lesions: A new subtype of gastric hyperplastic polyps in the stomach. *Clin Endosc*. 2018 Nov 21;51(6):558–62.
  294. Han A-R, Sung CO, Kim KM, Park C-K, Min B-H, Lee JH, et al. The clinicopathological features of gastric hyperplastic polyps with neoplastic transformations: a suggestion of indication for endoscopic polypectomy. *Gut Liver*. 2009 Dec 31;3(4):271–5.
  295. Stolte M, Sticht T, Eidt S, Ebert D, Finkenzeller G. Frequency, location, and age and sex distribution of various types of gastric polyp. *Endoscopy*. 1994 Oct;26(8):659–65.
  296. Laxén F, Sipponen P, Ihamäki T, Hakkiluoto A, Dortscheva Z. Gastric polyps; their morphological and endoscopical characteristics and relation to gastric carcinoma. *Acta Pathol Microbiol Immunol Scand A*. 1982 May;90(3):221–8.
  297. Omori T, Kamiya Y, Tahara T, Shibata T, Nakamura M, Yonemura J, et al. Correlation between magnifying narrow band imaging and histopathology in gastric

- protruding/or polypoid lesions: a pilot feasibility trial. *BMC Gastroenterol.* 2012 Feb 22;12:17.
298. Kanesaka T, Sekikawa A, Tsumura T, Maruo T, Osaki Y, Wakasa T, et al. Dense-type crypt opening seen on magnifying endoscopy with narrow-band imaging is a feature of gastric adenoma. *Dig Endosc.* 2014 Jan;26(1):57–62.
  299. Yao K, Iwashita A, Nambu M, Tanabe H, Nagahama T, Maki S, et al. Nature of white opaque substance in gastric epithelial neoplasia as visualized by magnifying endoscopy with narrow-band imaging. *Dig Endosc.* 2012 Nov;24(6):419–25.
  300. Colling C, Asztalos I, Buchner AM, Chandrasekhara V. Mo2037 Narrow-Band Imaging Classification System for Gastric Polyps May Reduce the Need for Biopsies. *Gastrointest Endosc.* 2017 May;85(5):AB531.
  301. Muehldorfer SM, Stolte M, Martus P, Hahn EG, Ell C, Multicenter Study Group “Gastric Polyps.” Diagnostic accuracy of forceps biopsy versus polypectomy for gastric polyps: a prospective multicentre study. *Gut.* 2002 Apr;50(4):465–70.
  302. Brown H, Wyatt S, Croft S, Gail N. SCOPING THE FUTURE. An evaluation of endoscopy capacity across the NHS in England. London: Cancer Research UK; 2015 Sep.
  303. Ross-Innes CS, Debiram-Beecham I, O’Donovan M, Walker E, Varghese S, Lao-Sirieix P, et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case-control study. *PLoS Med.* 2015 Jan 29;12(1):e1001780.

Figure 1






Figure 2




Figure 3






Figure 4




Figure 5




Figure 6




Figure 7

